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ABSTRACT 
 
 Cancer represents the second leading cause of death in the United States. 
For many malignancies, currently available treatment options offer little long-
lasting survival benefits to patients. However, recent studies have shown 
immunotherapeutic approaches to be an attractive strategy to cancer treatment. 
While many current immunotherapeutic strategies convey durable responses, 
such responses are only seen in a minority of patients. An increased 
understanding of the mechanisms governing tumor immunogenicity and the 
biology of immune responses is crucial to improving upon the efficacy of current 
and future cancer immunotherapies. Histone deacetylases (HDACs), enzymes 
classically associated with regulation of gene expression, have been therapeutic 
targets in various cancers for several years due to their involvement in cell 
growth.  However, it has become increasingly clear that HDACs are intimately 
involved in regulating both the immunogenicity of tumor cells and immune 
response of leukocytes and lymphocytes. In order to expand upon this growing 
knowledge, the therapeutic efficacy of the pan-HDAC inhibitor LBH589 in the 
treatment of melanoma was studied. The results presented here demonstrate 
that LBH589 is a potent inhibitor of growth in a wide variety of melanomas 
through induction of cell cycle arrest and apoptosis. Additionally, LBH589 
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increases the immune visibility of melanoma cells by increasing expression of 
several immune associated cell surface markers (e.g. MHC I, MHC II, CD80, 
CD86) in addition to upregulating expression of melanoma differentiation 
antigens. Furthermore, LBH589 treatment of immune cells results in an 
enhanced pro-inflammatory phenotype of both APCs and T-cells. These 
combined effects result in better activation of T-cells and ultimately prolonged 
survival in LBH589 treated, melanoma-baring mice. To further the understanding 
of the role of individual HDACs in the T-cell response, the biology of the newest 
HDAC, HDAC11, was further assessed. To this end, it is shown that HDAC11 is 
differentially expressed in T-cell populations, and expression is rapidly decreased 
following activation. Utilizing an HDAC11 knockout (HDAC11KO) mouse strain, it 
is found that both CD4+ and CD8+ T-cells lacking HDAC11 have an enhanced 
type 1 effector function characterized by increased proliferation and secretion of 
IL-2, TNF and IFN-γ. Additionally, HDAC11KO CD8+ T-cells have increased 
expression of both granzyme B and perforin. HDAC11KO T-cells also 
demonstrate enhanced resistance to inhibition by Tregs and anergy formation. 
As a possible mechanism for the observed phenotype, it is also demonstrated 
that HDAC11KO T-cells produce elevated levels of the transcription factors 
Eomes and T-bet, both at the basal state and post-activation. In vivo, T-cells 
lacking HDAC11 have a more potent and robust ability to cause GvHD and 
mediate an enhanced anti-tumor response. Collectively, these results 
demonstrate that targeting of HDACs is a viable approach to cancer 
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immunotherapy, and that targeting of specific HDACs may be an attractive 
strategy for optimizing immunotherapy efficacy while minimizing side effects.  
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CHAPTER 1 
Introduction 
Cancer 
Individuals in the United States have a 1 in 3 risk of developing and a 1 in 
5 chance of dying from cancer in their lifetime1. While the overall incidence and 
mortality rates for cancer have been slowly declining for the past several 
decades, the need for more efficient and novel therapeutic strategies is of vital 
importance as ever. Indeed, contrary to the overall trend, some malignancies 
such as metastatic melanoma have continually increased in incidence over the 
past 25 years. In the period between 1950 and 2000, the incidence of melanoma 
increased over 600%2. 
 
Melanoma 
Skin cancers are the most common malignancies in the United States.  
Although melanoma makes up a minority of these cases in terms of incidence, it 
accounts for a majority of skin cancer-related mortality1. Currently, patients 
diagnosed with metastatic melanoma face a 5-year survival rate of 15%, and few 
FDA approved therapies for metastatic melanoma provide significant survival 
advantages to patients3. Illustrative of this, in 2008, the average survival time for 
metastatic melanoma patients enrolled in phase II clinical trials was 6.2 months4.  
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Melanoma and the Hallmarks of Cancer 
In 2000, a landmark paper by Hanahan and Weinberg detailed a 
hypothesis that all cancers have a set of six hallmarks: sustained proliferative 
signaling, evasion of growth suppression, ability to metastasize, replicative 
immortality, ability to induce angiogenesis and resistance to cell death5. These 
hallmarks are well exemplified in melanoma. In fact, melanoma represents one of 
the most well studied cancers due to the ease of access to samples and it being 
one of the easiest cancers to culture6. However, despite this, melanoma remains 
a highly deadly disease with dismal current therapeutic options, due, at least in 
part, to the complexity of the disease. The following paragraphs will discuss 
examples of each of original hallmarks of cancer. In lieu of an exhaustive list, 
selected examples are meant to illustrate the complexity of melanoma.  
The first of these hallmarks, self-sufficiency in proliferative signaling, can 
be accomplished through multiple, well-described mutations in melanoma. Ninety 
percent of melanomas have mutations in the mitogen activated protein kinase 
(MAPK) pathway7, the pathway that in normal cells is activated in response to 
cytokine, growth factor or hormone receptor stimulation. One common set of 
mutations in the MAPK pathway is activating mutations in the RAS family of 
GTPases. The three members of the RAS family of genes represent the most 
commonly mutated oncogenes in human cancers8. In melanoma, NRAS is the 
most common mutated member of the family. It is estimated that 26% of human 
melanomas have mutations in the NRAS gene7. KRAS and HRAS are less 
commonly mutated in melanoma with occurrences of 2% and 1% respectively9. 
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BRAF, a signaling protein immediately downstream of RAS signaling in the 
MAPK pathway, represents the most commonly mutated gene in melanoma with 
a 66% mutation frequency10. Mutations are always in the kinase domain of BRAF, 
with 80% of mutations being the activating V600E mutation11.  
A second pathway important in melanoma proliferation is the 
PI3K/AKT/mTOR pathway. With the advent of MAPK pathway inhibitors, it has 
become evident that PI3K pathway can be a secondary pathway used by 
melanoma to sustain proliferative signaling and, in turn, form resistance to 
inhibitors of the MAPK pathway12. Indeed, the PI3K pathway is upregulated in 
70% of melanomas7. While mutations in PI3K itself are uncommon, mutations in 
other members involved in the pathway such as c-kit and PTEN, a negative 
regulator of the MAPK pathway, are more common13,14.  
The second requirement outlined in the hallmarks of cancer is evasion of 
growth suppression. One way in which this occurs in melanoma is through the 
cycline dependent kinase inhibitor 2A (CDKN2A) locus. This locus contains two 
genes, p16 and p14. The p16 protein prevents phosphorylation of retinoblastoma 
protein, thereby preventing G1 to S-phase progression. The p14 protein works on 
a separate, growth-suppression pathway though stabilization of p53 protein15. 
Hypermethylation, an epigenetic change silencing gene expression, of the 
CDKN2A promoter region is present in 19% of primary and 33% of metastatic 
melanomas16. Other mechanisms through which melanomas are known to evade 
growth suppression include inactivation of the aforementioned PTEN protein, or 
overexpression of cyclin-D15,15. 
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The third requirement is resistance to apoptosis. The most well known 
mechanisms though which many cancers achieve this is through p53 mutations. 
In melanoma, p53 is mutated in 5-25% of patients17. Separately, loss of 
apoptosis activating factor 1 (APAF-1) is common in metastatic melanoma. As 
the name implies, APAF-1 activates pro-caspase 9 and encourages apoptosis18. 
Furthermore, loss of APAF-1 results in chemotherapeutic resistance of 
melanoma19. Also of high importance in the apoptotic resistance of melanoma 
are members of the Bcl-2 family of genes. Members of this family can be anti-
apoptotic or pro-apoptotic in their function. The Bcl-2 protein itself and Mcl-1, 
anti-apoptotic members of the family, are known to be highly expressed in 
melanomas20,21. The role of pro-apoptotic members of the family, such as Bax 
and MITF, in melanoma are less well understood15.  
In cancers, replicative immortality, the fourth of the hallmarks, is often 
associated with increased telomerase (TERT) activity. Melanomas are no 
different in this regard. TERT activity is elevated in melanomas compared to 
benign nevi and surrounding normal skin22. Additionally, MYC, a known proto-
oncogene and transcription factor controlling cell proliferation, has a role in 
inducing TERT expression22.  
Induction of angiogenesis in melanoma, like all solid tumors, is known to 
occur through increased expression of vascular endothelial growth factor 
(VEGF)23. A second method of angiogenesis is through expression of follicular 
growth factor (FGF). FGF has been shown to be expressed by melanomas, but 
not by normal melanocytes24. FGF expression in melanoma is important in that it 
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not only stimulates angiogenesis, but also stimulates proliferation of tumor 
cells25,26.  
The final of the original hallmarks of cancer is the ability to metastasize. A 
variety of genes have been implicated in ability of melanoma to metastasize and 
invade other tissues. Amongst these, SLUG, a transcription factor initiating the 
epithelial-mesenchymal switch27, is known to be essential for melanoma to 
metastasize28. One consequence of SLUG activation is down-regulation of E-
cadherin, a transmembrane protein involved in cellular adhesion. Experimental 
overexpression of E-cadherin alleviates melanomas ability to metastasize, and 
expression of E-cadherin has been shown to oscillate with melanoma 
progression, in phase with its ability to metastasize and invade tissues29. Matrix 
metalloproteinases (MMP) -2 and- 9, also have known roles in melanoma 
invasion due to their roles as type IV collagenases30.  
 
Current Therapeutic Approaches to Melanoma 
For melanoma patients, course of treatment is dictated by stage of 
disease. Early stage melanomas often require no more than surgical excision. 
However, metastatic melanomas have proven exceptionally difficult to treat. Until 
recently, only two treatments were available for stage IV disseminated melanoma, 
dacarbazine and IL-2. However, recently vemurafenib and ipilimumab have also 
received FDA approval for the treatment of metastatic melanoma. Dacarbazine, a 
DNA alkylating agent, and vemurafenib, a tyrosine kinase inhibitor with efficacy in 
melanoma bearing a BRAF V600E mutation, target melanoma cells directly as 
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discussed in the paragraphs below31. Illustrative of the current ineffectiveness of 
current melanoma therapies, dacarbazine, the most established treatment for 
disseminated melanoma, has not been proven to improve patient survival32. 
Resultantly, evaluation of novel metastatic melanoma therapies and rational 
combination approaches are ongoing.  
 The high incidence of mutations in the MAPK pathway in melanoma has 
made therapeutic targeting of this pathway an attractive avenue. Particularly, 
melanomas with BRAF mutations are often oncogene addicted10, and the kinase 
domain of said protein has proven to be amenable to small molecule inhibitor 
design. Vemurafenib, which received FDA approval for the treatment of 
metastatic melanoma in August 2011, is one such BRAF targeted agent, with 
activity against V600E BRAF mutant melanoma33. Vemurafenib treatment has 
proven to significantly improve progression free survival and overall survival, with 
durations of response in the range of several months34. A second inhibitor, 
dabrafenib, having activity against both V600E and V600K BRAF, is currently in 
phase III clinical trials35. Alternatively, targeting of MEK proteins offers the 
advantage of being upstream of both RAF and RAS proteins in the pathway. 
Trametinib, an inhibitor of MEK1 and MEK2 has undergone evaluation in phase 
III trial. In this study, trametinib improved progression free survival 3.3 months 
longer (4.8 months vs. 1.5 months) than standard chemotherapy36.  
 While MAPK pathway inhibitors have demonstrated efficacy, resistance to 
said inhibitors quickly develops with a combined median time until resistance of 
6-7 months37. Additionally, 15% of patients receiving MAPK pathway inhibitors 
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are unresponsive38. As such, combinations of BRAF and MEK inhibitors have 
been evaluated. A phase I/II trial of darafenib and trametinib combination showed 
an increased response rate and duration of progression free survival versus 
monotherapies39. Another strategy in overcoming MAPK pathway inhibitor 
resistance is through additional targeting of the PI3K/AKT/mTOR pathway. As 
previously discussed, this pathway allows a secondary mechanism through 
which melanomas can retain proliferative signaling even in the presence of 
MAPK pathway inhibition. Synergy by MAPK and PI3K pathway inhibitors has 
been experimentally demonstrated40, and as such, combinations of inhibitors are 
undergoing clinical trials. For example, combinations of vemurafenib with the 
PI3K inhibitors sonolisib or BKM120 are currently in early phase clinical trials33. 
Additionally, clinical trials of vemurafenib in combination with AKT or mTOR 
inhibitors are being planned33. 
 Combination therapies outside of these combined pathways are also 
being explored. For example, VEGF inhibition alone has proven to be a poor 
therapeutic strategy in melanoma; however, combination therapies are being 
explored to improve results33. Additionally, the HSP90 inhibitor XL888 has 
demonstrated ability to reverse BRAF inhibitor resistance in melanomas41. 
Consequently, evaluation of vemurafenib and XL888 in patients with 
disseminated melanoma is underway33.  
 While the majority of melanomas present with mutations in BRAF, there 
exist melanomas that are BRAF wild-type. As such, alternative inhibitors require 
development. Outside of immunotherapies, this area remains relatively 
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unexplored. However, as KIT is mutated in a subset of melanomas, inhibition of 
this family continues to be evaluated33. KIT inhibitors, such as imatinib, have 
shown mixed results. This may be in part that not all KIT mutations in melanoma 
are driver mutations42.  
 Targeted therapies against metastatic melanoma remain wholly 
inadequate. While major scientific and clinical advances have been made in the 
last few years, and the resultant increases in survival time of patients are 
statistically significant, these increases are still measured in terms of weeks and 
months. Consequently, metastatic melanoma therapy remains a large obstacle 
for both the scientific and medical community.   
 
Cancer and the Immune System 
  Cancer represents a failure of the immune system to recognize abberant 
changes in normal cellular homeostatis. In 1909 Paul Ehrilich proposed that the 
immune system prevented the development of tumors43. However, this 
hypothesis remained controversial for nearly a century.  It was assumed that due 
to the nature of cancer being “self” that it was unrecognizable to the immune 
system. In support of this skepticism, experiments using athymic mice reveal no 
increased incidence of cancer44. However, overlooked was that athymic mice 
possess innate immune cells, NK cells and non-classical populations of T-cells45. 
With the advent of other immunodeficient mouse models, the importance of the 
immune system in controlling the formation of cancer became clear. It is now 
known that many tumors bear antigens that are recognizable to the T-cells. 
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Indeed, many patients possess populations of T-cells reactive to their tumors46. 
With the now established knowledge that the tumor development is controlled by 
the immune system and many established tumors are recognized by the immune 
system, the question in more recent years has turned to addressing the 
mechanism by which the immune response fails. To address this question, an 
understanding of the immune system itself is crucial.  
The immune system is divided into two separate arms: the innate and 
adaptive immune system. One major defining difference between these two arms 
is antigen specificity. While the innate immune system relies on germ-line 
encoded receptors (e.g. TLRs) to recognize pathogens and other targets, the 
adaptive immune system is able to generate an overwhelming number of antigen 
specific receptors through somatic mutation of genes coding for T-cell or B-cell 
receptors. This allows for the adaptive immune system to recognize and respond 
to antigens that it has not previously encountered. The second defining 
characteristic of the adaptive immune system is the development of memory. At 
its most simplistic, immunological memory refers to the ability of cells to respond 
to antigen re-challenge in a rapid and robust manner due to the persistence of 
antigen-specific populations of immune cells post-initial encounter with the 
antigen.  
The components of the adaptive immune system include B-cells and T-
cells. T-cells are further divided into two main classes, CD4+ or T helper cells 
and CD8+ or cytotoxic T-cells. In the setting of cancer, T-cells represent the 
critical cell type for tumor destruction. Classically CD4+ T-cells orchestrate the 
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immune response, while CD8+ T-cells are the ultimate effector cell type 
responsible for the direct destruction of transformed cells. However, in the 
absence of the innate immune system, the T-cell response is crippled.  Innate 
immune cells, such as dendritic cells and macrophages function as antigen 
presenting cells (APCs), and bridge the gap between the adaptive and innate 
immune system. APCs function to uptake and present MHC bound antigen to 
lymphocytes, as well as direct the type and magnitude of the immune response 
by way of co-stimulation and cytokine signaling. It should be noted that tumor 
cells can act as non-professional APCs through MCH I and MHC II expression, in 
addition to expression of various co-stimulatory or co-inhibitory molecules and 
production of cytokines47,48.  
Experiments showing that immunocompromised mice had increased 
incidences of tumor formation also revealed that the nature of the tumors in those 
mice was different than those in wild-type mice; tumors from 
immunocompromised mice tumors had increased immunogenicity49. This and 
other experiments lead to formation of the theory of cancer immunoediting. This 
theory states that due to the selective pressures of the immune system, tumor 
cells that have decreased immunogenicity or increased immunosuppressive 
mechanisms are selected for50. Three phases exist in cancer immunoediting: 1) 
elimination, 2) equilibrium, and 3) escape51. In the elimination phase, dying tumor 
cells and damaged nearby tissue release damage associated molecular patterns 
(DAMPs), type-1 and type-2 interferons, and other factors recruiting various 
immune cells. APCs uptake of tumor antigens leads to an adaptive immune 
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response. Activated CD4+ and CD8+ T-cells mount an anti-tumor response 
through the production of effector molecules such as IFN-γ and perforin50. Under 
ideal circumstances this leads to tumor clearance and formation of long lasting 
memory. However, if the tumor cells are not cleared, the cells move into an 
equilibrium phase. During this phase, the tumor cells are controlled but not fully 
eliminated by the immune system. Tumor cells may remain quiescent52 or may 
proliferate and be balanced out by apoptosis53. This state of equilibrium can 
remain throughout an individual’s lifetime54. The final phase, escape, occurs 
when the continued immune pressure, coupled with the genetic instability of the 
tumor, causes tumors to lower their immunogenicity becoming unrecognizable to 
the immune system, become insensitive to immune effector mechanism, and/or 
inducing an immunosuppressive microenvironment50.  
 Given the intimate involvement of the immune system in the development 
and progression of cancer, interest in manipulating the immune response to shift 
the balance back towards the anti-tumor response holds great therapeutic 
promise. Termed cancer immunotherapy, this general approach can be divided 
into two main subtypes: active and passive. Passive immunotherapy utilizes 
immune product infusions (e.g. antibodies or cytokine therapies) that are short 
lived. Active immunotherapies induce the host immune system to respond 
against the resident tumor (e.g. vaccination)55.  
 Passive immunotherapeutic approaches have had several successes thus 
far. Currently there are one dozen FDA approved antibodies for use in various 
cancers (Table 1)56. The mechanisms through which antibody therapies work are 
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quite diverse.  Antibody binding to its antigen may: act as an agonist or 
antagonist to receptors, allow directed delivery of a cytotoxic agent, result in 
complement dependent killing, and/or recruit immune effector cells56. Sometimes 
classified separately, a second type of passive immunotherapy is infusions of 
cytokines such as IL-2 or IFN-α2b57,58. Cytokine infusions are thought to act 
through multiple mechanisms including stimulation of immune cell proliferation 
and response, suppression of oncogenes and angiogenesis, and enhancing 
expression of MHC I and MHC II. However, cytokine therapies are notorious for 
having significant side effects58. Coupling the limited therapeutic benefit58,59 with 
the adverse side effects shows, and it is evident that modern cytokine therapies 
are of limited value. This may be rectified by future exploration of combination, 
lower dose cytokine therapies that better replicate physiological responses55,60.  
 
Table 1 – FDA Approved Antibody Therapies with Indications in Cancer 
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 A major form of active immunotherapy is through the use of vaccines. 
Cancer vaccines can be classified as polypeptide based, whole cell, or viral 
vector. Polypeptide based vaccines utilize tumor associated antigens61 or tumor 
lysates62, while whole cell vaccines use irradiated autologous or allogenic tumor 
cells. Viral vector vaccines are used to transfect tumor cells to overexpress tumor 
associated antigens or cytokines63,64. More recently, dendritic cell based 
vaccines have been attempted. In this method, autologous dendritic cells are 
stimulated ex vivo in the presence of tumor or tumor antigen. These cells are 
then re-infused into patients to activate T-cells65. Overall, cancer vaccination in 
the treatment of established tumor has proven to be difficult, but recent results 
have showed optimism66.  
Alternative to vaccination, a second method of active immunotherapy is 
adoptive T-cell therapy. In this method, T-cells are cultured ex vivo and antigen 
specific T-cell populations expanded then re-infused into patients67. Adoptive T-
cell therapy will be discussed in greater detail further in the chapter.  
 Immunotherapies are not without their hurdles and limitations. For 
instance, as a consequence of the deletion of self-reactive T-cells, the presence 
of tumor reactive lymphocytes is often limited. Even with sufficient populations of 
tumor reactive T-cells, these T-cells must overcome the immunosuppressive 
mechanisms generated by the tumor. Given that these hurdles are overcome, 
immunotherapies can often lead to adverse events such as autoimmunity or non-
specific inflammation68. For instance, anti-CTLA4 treatment of metastatic 
melanomas can lead to vitiligo69. 
	  	   14	  
Immune Evasion by Melanoma 
As a follow-up to their landmark 2000 paper, in 2011 Hanahan and 
Weinberg published a review detailing four additional hallmarks: tumor promoting 
inflammation, genome instability, dysregulation of cellular metabolics, and 
evasion of immune destruction70. Despite melanoma being one of the most 
immunogenic cancers71, the very presence of this disease in immunocompetent 
patients illustrates that melanoma is capable of avoiding or altering the immune 
response. This is mainly through production of an immunosuppressive 
microenvironment, though the known mechanisms though which this is 
accomplished are diverse.  
The importance of the immune system in the development and control 
ofmelanoma is well supported by a number of observations. First, 
immunosuppression is known to increase the risk of melanoma development72. 
Second, a large percentage of primary melanomas spontaneously regress in 
patients, even in the absence of treatment73. In fact, this is thought to occur more 
frequently in melanoma than other solid tumors73. Tumor infiltrating CD4+ and 
CD8+ T-cells are characteristic of these spontaneously regressing tumors74. 
Histological analysis of early stage, horizontal expanding, primary melanomas 
often presents with lymphocyte infiltration. Indeed, this is one criterion by which 
early malignant melanomas are distinguished from nevi75. Additionally, increased 
numbers of tumor infiltrating lymphocytes (TILs) is correlated with increases in 
survival times of melanoma patients76.  
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 More direct evidence for the importance of the immune response in 
melanoma comes from the ever-growing body of tumor-associated antigens, or 
antigens expressed on melanomas that are recognizable by autologous T-cells 
or antibodies. These antigens are classified into three categories: 1) 
differentiation antigens (e.g. gp100, MART-1, tyrp2) 2) cancer testis antigens (e.g. 
MAGE A1, NY-ESO-1) and 3) mutated/aberrantly expressed antigens (e.g. CDK4, 
MUM-1, beta-catenin)77-79. The expression of such antigens has led to the on 
going testing of melanoma-antigen based vaccine therapies.  
To avoid eradication, melanoma can direct the immune system toward 
tolerance. One mechanism through which this is accomplished is co-opting cells 
of the immune system such as regulatory T-cells (Tregs), myeloid derived 
suppressor cells (MDSCs), and tumor associated macrophages (TAMs). 
Evidence for the role of Tregs in melanoma is supported by increased numbers 
of Treg cells in metastatic melanoma patients80, and particularly high populations 
of Tregs in primary tumors, metastases, and affected lymph nodes81,82. Indeed, it 
has been shown that some of these Tregs present are specific for melanoma 
antigens83. A second immune cell group that is known to play a suppressive role 
in melanoma are MDSCs84. MDSCs are a heterogenous group of immature 
leukocytes that often become a suppressive population in tumor bearing hosts85. 
The immunosuppressive activity of MDSCs is, in part, mediated by their 
production of nitric oxide and reactive oxygen species resulting in down-
regulation of the T-cell response86. A third cell type involved in the 
immunosuppression by melanoma are TAMs. Tumor infiltrating macrophages, 
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while possessing the ability to be pro-inflammatory, are often polarized by the 
tumor microenvironment towards anti-inflammatory, pro-tumorigenic phenotype 
known as M287. TAMs have proven to be powerful foes in the setting of cancer 
due to their ability to promote tumor growth through secretion of various factors 
including GFP, PDGF, bGFG and TGF-β88. Additionally, through the expression 
of VEGF and other factors, TAMs are able to stimulate angiogenesis89. Finally, 
and paramount, the anti-inflammatory phenotype of TAMs results in down-
regulation of the T-cell and NK cell effector responses90.  
A second set of mechanisms melanoma utilizes is the expression of 
immunosuppressive cytokines. For example, melanoma cells often produce 
transforming growth factor-β (TGF-β)91. TGF-β has anti-proliferative effects on 
cells, however, melanoma cells are resistant to these effects92. Instead, TGF-β 
secretion by melanoma cells results in induction of suppressive immune cells93 
and suppression of T-cell effector function94. Melanoma cells can also express 
IL-695.  IL-6 has a repertoire of sometimes opposing roles. Chronic exposure to 
IL-6 in melanoma results in a switch from IL-6 being a suppressor of growth to an 
enhancer96. Additionally, IL-6 has a role in suppressing dendritic cell 
maturation97. Immature dendritic cells can suppress the function of other dendritic 
cells and skew differentiation of tumor macrophages resulting in populations of 
TAMs98. Furthermore, melanomas can produce the anti-inflammatory cytokine IL-
10, production of which is not seen in normal skin samples99. The significance of 
IL-10 production in melanomas is illustrated by reports of increased levels of IL-
10 being significantly correlation with shorter survival times in metastatic 
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melanoma patients100,101. IL-10 can confer immunological advantages to 
melanoma cells through a variety of mechanisms including decreased expression 
of major histocompatability molecules (MHC)102, induction of expression of co-
repressive molecule B7-H4 on TAMs103, and conversion of dendritic cells into 
toleragenic dendritic cells104 amongst other mechanisms105. 
Finally, melanoma can avoid immune destruction through altering the 
expression of immunogenic surface markers. Among these markers is the co-
inhibitory molecule PD-L1106,107. PD-L1 is the ligand for programmed cell death-1 
(PD-1), a member of the CD28 family expressed on T-cells and other immune 
cells108,109. Expression of PD-L1 by melanoma cells, and subsequent 
engagement of PD-1 by PD-L1 results in inhibition of T-cell growth, cytokine 
production, or induction of apoptosis110-112. Melanoma may also avoid immune 
detection by down regulating expression of MHC I (aka HLA class I)113. This is 
particularly important mechanism as melanoma expresses such a diverse array 
of recognizable antigens. One study concluded that 67% of melanomas had 
reduced expression of HLA class I114. The mechanisms through which this down-
regulation is achieved are diverse113.  
 
Immunotherapeutic Approaches to Melanoma Treatment 
 Given its the well established role in melanoma, the immune system and 
its interactions with melanoma have been ongoing therapeutic targets. Attempts 
at melanoma immunotherapy have largely been met with failure. However, the 
lessons learned from early failures have lead to more recent advances and 
	  	   18	  
successes. Indeed, while chemotherapeutic approaches to metastatic melanoma 
treatment offer no survival benefit115, some immunotherapeutic approaches have 
lead to durable responses in a minority of patients. Currently, three 
immunotherapies are FDA approved for the treatment of metastatic melanoma, 
IL-2 and IFN-α2b (not indicated in stage IV), pro-inflammatory cytokines 
administered systemically, and ipilimumab, a CTLA-4 blocking antibody.  
IL-2 was approved for the treatment of metastatic melanoma in 1998116. 
IL-2 acts by stimulation and maintenance of lymphocytes and augmentation of 
natural killer cell activity. One study has reported that administration of high dose 
IL-2 results in a 16% overall response rate117. Forty-four percent of those having 
responses had 5-year or longer survival benefit118. However, IL-2 administration 
often results in severe side effects115. A second cytokine, IFN-α2b, is also FDA 
approved in the treatment of metastatic melanoma. Use of IFN-α2b has an 
overall response rate of 22%119. Much like IL-2, administration of IFN-α2b is 
associated with significant side effects. To minimize these side effects, pegylated 
IFN-α2b was FDA approved in 2011116.  It should be noted that IFN-α2b is not 
indicated for use in stage IV melanoma.  
 The first attempt at use of vaccine as a melanoma therapy occurred in the 
1970’s. Unfortunately, no objective survival advantage was seen in those early 
trials120.  Since that time, several different approaches to vaccine-based 
immunotherapy have been attempted including peptide based and dendritic cell 
therapies, and these trials have utilized a variety of identified melanoma antigens. 
The results of these approaches have been mixed, with some trials reporting no 
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survival advantages, and objective survival advantages being seen in a minority 
or subset of patients in other trials121. Suffice to say, vaccine based approaches 
to melanoma therapy have proven difficult.  
Recently, clinical use of antibodies blocking the co-inhibitory molecule 
CTLA-4 on T-cells has been explored. CTLA-4 competes with CD28 for binding 
of B7 molecules on APCs. However, unlike CD28, CTLA-4 ligation results in 
suppression of the inflammatory response.  In phase II clinical trials, ipilimumab, 
a CTLA-4 blocking antibody, showed activity in metastatic melanoma patients 
with a 30% survival rate at 2-years out in the 10mg/kg dose group122. Such 
results lead to the 2011 FDA approval of ipilimumab for the treatment of 
metastatic melanoma123.  More recently, the efficacy of blocking PD-1 on T-cells 
or PD-L1 on melanoma cells was evaluated in phase 1 studies. PD-1 blockade 
resulted in objective response in 28% of patients with metastatic melanoma124, 
while PD-L1 blockade, at the time of reporting, resulted in a 17% objective 
response rate125. Clinical evaluation is ongoing.  
Adoptive T-cell therapy has demonstrated profound efficacy in 
melanoma126,127. Generally, the process of adoptive immunotherapy involves the 
ex vivo identification and expansion of autologous tumor antigen specific T-cells. 
These cells are then transferred back into patients. Clinical trials using adoptive 
transfer of tumor infiltrating lymphocytes following lymphodepletion have resulted 
in objective response rates as high as 72%, with many durable responses127. 
While adoptive T-cell therapy has proven effective, not all patients undergo tumor 
regression, allowing for further optimization. Persistence of T-cells after adoptive 
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transfer correlates with patient response, so attempts at co-administration of IL-2 
have been attempted yielding poor results128. Attempts have also been made to 
transfer T-cell receptors from patients responding from therapy into adoptively 
transferred T-cells, but this approach has been largely unsuccessful129,130. More 
recently, the use of chimeric antigen receptor (CAR) technology to improve 
adoptive T-cell therapy has been explored. CAR technology utilizes an 
extracellular antigen recognition domain, generally an antibody, coupled to the 
transmembrane and intracellular signaling domains of the CD3 zeta chain. 
Second-generation CAR technology also links the intracellular signaling domains 
of co-stimulatory molecules (e.g. CD2i, 4-1BB) to the engineered receptor. This 
creates a T-cell that is activated upon recognition of antigen, even in the absence 
of that antigen being MHC bound or proper co-stimulation. While CAR 
technology has yet to reach clinical trials in melanoma, it has shown clinical 
benefit in other tumor models131,132. However, adverse events have been 
reported due to the potent nature of CARs133,134, and caution must be exercised 
in their future use. Overall, adoptive T-cell therapy, especially relative to other 
therapeutic approaches in metastatic melanoma, is emerging to be a powerful 
therapeutic strategy.  
 
Histone deacetylases 
 In an organism, all somatic cells, with a few special exceptions, contain 
the same DNA sequences. As such, cells must possess machinery that allows 
the expression of different genes, and repression of others, that is specific to the 
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cell type and environmental context. Such machinery falls under the category of 
epigenetics. Epigenetic machinery includes histone modifications (methylation, 
acetylation and ubiquination), DNA methylation, and interfering RNAs. These 
modifications and mechanisms allow for cells containing the same DNA to have 
different and distinct functions. Given such a powerful influence, epigenetics, 
while arguably poorly defined, is an important concept that has garnered 
increasing amounts of attention.   
Histone acetylation status represents a major mode of epigenetic 
regulation. Two classes of enzymes are known to work in opposition to regulate 
the chromatin state through acetylation: histone acetyltransferases (HATs) and 
histone deacetylases (HDACs).  As their name implies HDACs are a class of 
enzymes named for the observation of their involvement in removing acetyl 
groups from histone lysine residues. However, since the initial observation and 
naming, the role of HDACs has expanded to include many non-histone targets, 
perhaps reflecting a shortcoming in the term histone deacetylases.  
In humans, HDACs are grouped by their phylogenetic relatedness and 
sequence homology into four main classes: class I (HDAC1, HDAC2, HDAC3, 
HDAC8), class II (HDAC4, HDAC5, HDAC7, HDAC9, HDAC6, HDAC10), class III 
(sir2-like or sirtuin proteins), and class IV (HDAC11). Class II HDACs are further 
divided into class IIa (HDAC4, HDAC5, HDAC7, HDAC9) and class IIb (HDAC6, 
HDAC10). Class I HDACs are clustered according to their shared homology with 
the yeast Rpd3 enzyme, and class II HDACs with their homology to yeast Hda1 
enzyme. The sole class IV HDAC, HDAC11, shares homology to both Rpd3 and 
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Hda1135. Classes I, II and IV are known as the classical HDACs, all of which are 
zinc-dependent enzymes, while the class III sirtuin proteins are NAD+ dependent 
enzymes. Classical HDACs all contain a N-terminal deacetylase domain, 
however HDAC6 contains two tandem deacetylase domains135. Thus far, crystal 
structures have only been resolved for HDAC8 and HDAC7135,136. The known 
localization of HDACs along with chromosomal location and mouse knockout 
phenotypes are listed in Table 2. 
Class I HDACS, excluding HDAC8, function as part of multi-protein 
complexes to regulate gene expression by way of chromatin remodeling. For 
example, as part of the nucleosome remodeling deacetylase (NuRD) complex 
Sin3, HDAC1 and HDAC2 complex with several other proteins to regulate 
transcription by controlling the acetylation state of histones. In general, 
deacetylated histone tails result in electrostatic attraction of the negatively 
charged DNA to the positively charged lysine residue. This conformation causes 
a condensed chromatin structure, heterochromatin, resulting in a physical state 
non-permissive to transcription. Inversely, acetylation of histone tails allows for a 
relaxation of the chromatin structure, generating a physical state, euchromatin, 
that is conducive to transcriptional activation of the associated gene. Furthermore, 
acetylation of histones can lead to the recruitment of bromo-domain containing 
transcriptional co-activators.  
Class IIa HDACs can be found both in the nucleus and the cytoplasm of 
cells, as members of this class of HDACs possess signaling sequences for 
nuclear import and export135. This suggests a distinct role from class I HDACs. 
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Indeed, class IIa HDACs are known to interact with non-histone substrates such 
as HSP70135.  The class IIb HDAC, HDAC6, exemplifies the non-histone 
influence of HDACs. HDAC6 appears to be mainly cytoplasmic137 with an 
assortment of known functions there. Foremost among these functions is the 
deacetylation of α-tubulin, giving HDAC6 a prominent role in cell motility and 
chemotaxis138. HDAC6 also regulates the acetylation of HSP90, allowing for 
HSP90 to associate with and activate glucocorticoid receptors139. Finally, HDAC6 
is known to play a key role in the delivery of misfolded proteins in aggresomes to 
proteases for destruction140.  
 
Table 2 – Histone Deacetylase Location and Knockout Mice 
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 HDAC11 is the most recently discovered HDAC, and lone member of the 
class IV HDACs. First identified in 2002141, compared to the other HDACs, 
relatively little is known about HDAC11. The HDAC11 gene is located on 
chromosome 3 in humans and chromosome 6 in mice142, the predicted protein 
product of which is a 39kDa monomeric protein, the smallest of the HDACs141. 
Indeed, the catalytic domain of HDAC11 is predicted to encompass the majority 
of the protein. Histone deacetylase assay results have shown that while HDAC11 
has deacetylase activity, it is relatively minor (~15% of that of HDAC3)141.  
 Using a FLAG-encoding HDAC11 plasmid transfection, HDAC11 
expression was shown in the nucleus, but not cytoplasm of cells. Using the same 
system, it was shown that HDAC11 associates with HDAC6141.  Indeed, an 
independent study showed that HDAC6 and HDAC11 have opposing roles in 
controlling the expression of IL-10 by APCs143. In this study it was shown that 
overexpression of HDAC11 in LPS activated macrophages results in a 
substantial decrease in IL-10 production, while overexpression of HDAC6 results 
in a substantial increase in production. Furthermore, when HDAC11 expression 
in dendritic cells is knocked down using shRNA, IL-10 production is increased. 
Additional to it’s function in APCs, in mouse macrophages HDAC11 has been 
demonstrated to negatively regulate expression of plasminogen activator inhibitor 
type-1 (PAI-1)144, a protein with known involvement in cancer metastasis145.  
Silencing of HDAC11 expression via siRNA results in increased PAI-1 expression, 
and chromatin immunoprecipitation revealed interactions between the PAI-1 
gene and HDAC11 in LPS stimulated macrophages144.  
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Expression of HDAC11 is highly tissue restricted, with expression at it’s 
highest in central nervous tissues, testis, and kidneys141. Interestingly, the tissues 
with greatest expression are those with low levels of cell division. In agreement 
with this observation, one study demonstrated that HDAC11 and Ki67 are rarely 
co-expressed in cells146.  The same study confirmed the initial report of nuclear 
localization of HDAC11. In addition, expression was highest in mouse 
oligodendrocytes, and overall mouse brain expression of HDAC11 had spatial 
patterns and increased in overall expression from birth to four weeks. A 
subsequent study by the same group further looking into the role of HDAC11 in 
oligodendrocytes showed that siRNA silencing of HDAC11 expression results in 
global histone 3 lysine 9 and 14 (H3K9/14) acetylation levels. Additionally, 
silencing results in decreased expression of myelin basic protein and proteolipid 
protein expression and ultimately morphological changes associated with 
maturation of oligodendrocytes147.  
Further among the few known roles of HDAC11 is its participation in 
regulating DNA replication during mitosis. In order to replicate DNA, Cdt1 and 
mini-chromosome maintenance (MCM) helicase must form the pre-replication 
complex during G1 phase. For this event to occur, the chromatin structure must 
be accessible. This is accomplished via histone acetylation by the histone 
acetyltransferase HBO1. As the cell progresses to S phase and DNA replication 
has occurred, the complex must be dislodged in order to prevent another round 
of DNA replication. Authors of one study demonstrated that this is accomplished 
by HDAC11 binding Cdt1, inhibiting Cdt1’s ability to induce chromatin unfolding. 
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This binding is enhanced in the presence of Geminin, a protein previously 
described to accumulate during S phase and negatively regulate DNA replication 
itself148.  
While mechanistic explanations remain to be found, aberrant HDAC11 
expression has also been reported in several cancers. Indeed, the initial 
description of HDAC11 tissue expression also demonstrated that HDAC11 
expression was extremely high in several cancer cell lines including: H1299 (non-
small cell lung carcinoma), T24 (urinary bladder carcinoma), SJRH30 
(rhabdomyosarcoma), SJSA-1 (osteosarcoma), and HCT116 (colorectal 
carcinoma)141. Aberrant expression of HDAC11 has also been shown in human 
glioblastomas149. More recently, HDAC11 has also been shown to be 
overexpressed in several carcinoma cells lines including breast (MCF-7), 
prostate (PC-3), ovarian (SK-OV-3) and colon (HTC116). Moreover, this same 
study reported that siRNA knockdown of HDAC11 alters metabolic activity and 
impairs viability of these cell lines150.  
In Hodgkin lymphoma cells, HDAC11 has been shown to regulate 
expression of OX40 ligand (OX40L)151. OX40L expression is generally 
associated with APCs. OX40L engagement of OX40 receptor, transiently 
expressed on activated T-cells, regulates T-cell survival and ultimately memory 
formation. Treatment of Hodgkin lymphoma cells with the HDACi MGCD0103 
results in increased expression of OX40L, while no differences are seen in 
treatments with the pan-HDACi vorinostat. As MGCD0103 has a more selective 
inhibitory profile that that of vorinostat, the role of HDAC11 was further 
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investigated to reveal that siRNA silencing of HDAC11 results in a similar 
increased in OX40L expression. However, this study did not further evaluate 
mechanistically how HDAC11 regulated expression.   
While currently lackluster, knowledge of the roles of individual HDACs is 
expanding at a high pace. This is due in part to the novelty of the field of 
epigenetics and the relatively recent discovery of the diversity of HDACs. As well, 
interest in HDACs stems from their potential in therapeutic targeting in several 
fields including psychiatric disorders, autoimmunity and cancer.  
 
HDACs in Cancer 
 While it is classically thought that gene mutations are the mode of 
dysfunction in cancer cells, it has become increasingly evident that epigenetic 
alterations play key roles in the development and progression of malignant cells. 
Abberations in DNA methylation were the first of these epigenetic abnormalities 
observed in cancer152. Thereafter, modifications to histones were discovered to 
play roles in tumorigenesis153. Indeed, gene-wide reductions in histone 4 lysine 
16 acetylation (H4K16ac) are common to nearly all human cancers154. Additional 
aberrant histone acetylation marks have been observed in various cancers, and 
in some cases can be reliable as prognostic indicators153,155. Such alterations in 
histone acetylation are known to occur through both genetic and non-genetic 
routes. Driver or passenger mutations of tumors can result in dysfunction of 
epigenetic “writers” or “erasers”155.  Alternatively, histone protein themselves can 
harbor mutations leading to changes in not only acetylation status, but 
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methylation as well156. Outside of direct mutation, environmental toxins such as 
arsenic and nickel can act as HDAC inhibitors and histone acetyltransferase 
inhibitors, respectively157,158. Such alterations in chromatin status can lead to 
events such as silencing of tumor suppressor genes, enabling tumor formation or 
progression155. Additionally, there is evidence that epigenetic alterations can 
result in random translocations159. 
 HDAC proteins themselves can also be aberrantly expressed in cancers. 
HDAC1 is overexpressed in breast160, colon161, gastric162, and prostate cancer163; 
HDAC2 in cervical164, colorectal165, and gastric cancer166; HDAC3 in colon 
cancer161; and HDAC6 in breast cancer167. As previously discussed, HDAC11 
expression is elevated in a variety of carcinomas and sarcomas141. 
 
Histone Deacetylase Inhibitors 
One of the earliest HDAC inhibitors (HDACi) to be identified was butyrate; 
however, at the time it was unknown that the target was histone deacetylases. In 
this early study, treatment of erythroleukemic cells with butyrate halted cell 
division168. Shortly thereafter it was discovered that butyrate treatment of 
erythroleukemic cells resulted in histone hyperacetylation, though the target 
molecules still remained unknown169. Finally, over a decade later, in 1990, the 
first report of the target of trichostatin A (TSA) being histone deacetylases 
emerged170.  
Currently two HDACi have been FDA approved for use a cancer 
therapeutics, suberoylanilide hydroxamic acid (SAHA) and romidepsin, both of 
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which having indications in cutaneous T-cell lymphoma171,172. Moreover, there 
are over two dozen small molecule inhibitors of HDACs, and a dozen or more of 
these have made it to various phases of clinical trials for various cancers173. 
Table 3 contains a semi-comprehensive list of current HDACi and their 
specificities. It should be noted, that beyond their predominate use in the setting 
of cancer therapy, HDACi have shown usefulness in treating various 
neurodegenerative174 and inflammatory disorders175. Based on their structure, 
HDACi can be classified into six classes: short-chain fatty acids, hydroxamates, 
benzamides, cyclic tetra peptides, electrophilic ketones or others173. 
A good deal of experimental evidence demonstrates the diversity of anti-
cancer activity of HDACi. Foremost, HDACi have tenfold or more selectivity for 
transformed cells over normal cells in their effects176. HDACi are well established 
to induce apoptosis in cancer cells, through intrinsic177-180 or extrinsic181-184 death 
pathways, or both185. The mechanisms through which apoptosis is induced by 
HDACi is bountiful including induction of mitochondrial dysfunction through 
enhanced production of reactive oxygen species (ROS)186, enhancement of TNF-
related apoptosis inducing ligand (TRAIL)187, downregulation of BCL-2180, 
induction of Bim expression188 and upregulation of Fas and FasL181. Beyond 
induction of apoptosis, HDACi can control tumor growth though induction of cell 
cycle arrest. Arrest in G1/S transition is characteristic of most HDACi173. This 
arrest results from retinoblastoma protein hypophosphorylation through induction 
of CDKN1A189 or repression of cyclin D and A190. Other mechanisms resulting 
from chromatin architecture changes have also been implicated in resulting G1/S 
	  	   30	  
arrests191,192. Though relatively rare, G2 arrests can also be induced by 
HDACi193. The mechanisms resulting in G2 arrests by HDACi remain unclear173.  
 
Table 3 – Inhibitors of Histone Deacetylases 
 
Third amongst their anti-cancer effects, HDACi can negatively influence 
angiogenesis. Individual HDACs have known roles in angiopoeisis, so HDACi 
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influence on the process is unsurprising. For example, class I HDACs are known 
to be involved with regulating the effects of VEGF through pVHL194. Type II 
HDACs have also been implicated by way of regulation of hypoxia inducible 
factor 1α (HIF-1α)195. Indeed, HDACi can downregulate several key factors in 
angiogenesis including VEGF196, bFGF197, and angiopoietin198 among others199.   
More recently, the immunomodulatory effects of HDACi have become 
evident. HDACi treatment is known to affect the expression of several 
immunologically important molecules on the surface of tumors including MHC I, 
MHC II, CD40, CD80, CD86 and ICAM1200,201. Moreover, HDACi has been 
shown to induce the expression of MICA and MICB, ligands for the NKG2D 
receptor, binding of which results in NK cell cytolytic response202,203. HDACi can 
also have differential effects on TLR genes, dependent on the HDAC inhibitor 
used204. Likewise, cytokine production is modulated in various cell types and 
according to HDACi used. For example, SAHA reduces serum levels of TNF, IL-1 
and IFN-g in an acute graft-versus-host disease model205. TSA and SAHA are 
both also known to down regulate expression of IL-12 in dendritic cells206. 
Furthermore, various HDACi can affect the expression of IL-6207, type-1 
interferons208, IFN-γ209 and CXCL1 in addition to the chemokine ligands CCL2 
and CCL7207. The diversity of immune responses seen as a result of HDACi are 
likely in part due to the influence of HDACi on STAT1209,210, STAT3211 and 
NFkB212, all of which are targets for acetylation/deacetylation and regulate 
cytokine and immune transcription factor expression. 
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As HDACi are administered systemically, an understanding of the effects 
that this pharmaceutical agents have on the adaptive immune response is 
essential. While less studied than their effects on cancer cells and APCs, HDACi 
have functional consequences on lymphocytes. For example, impairment in B-
cell development by disruption of HDAC1 and HDAC2213. Additionally, HDAC6KO 
mice display impaired IgG and IgM production214, suggesting that inhibition of 
HDAC6 may result in a similar phenotype.   
Unfortunately, only a handful of studies have addressed the influence of 
HDACi on T-cells, and the diversity of HDACi studied is limited. However, those 
studies investigating these effects have often shown largely that HDACi skew T-
cell responses towards a Th2 response, a major difficulty in the setting of cancer. 
For example, in murine T-ells treated with TSA, production of IL-2, IL-13, and 
IFN-γ is inhibited. Similarly, treatment with scriptaid or sodium butylate also 
reduces IFN-γ production215. A separate study demonstrated increased 
production of IL-4 and increased Th1 apoptosis in T-cells resulting from 
treatment with TSA. In human T-cells, HDACi have been shown to have similar 
influences, with TSA treatment resulting in IL-4 increases and IL-2 and IFN-γ 
decreases216. As well, TSA treatment has been shown to reduce the formation of 
IL-17 producing T-cells217. Finally, one study showed that treatment of antigen 
specific T-cells with TSA or butyrate enhances tolerance, a consequence of the 
cytokine skewing previously described218. 
To date, clinical applications of HDACi in the treatment of melanoma have 
been less than successful. In a phase II trial using MS-275 to treat previously 
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treated, stage IV refractory melanoma, patients were given 3mg biweekly or 7mg 
weekly in 4-week cycles. Unfortunately, no objective response was detected from 
either dose219. Similarly, in a phase I/II trail of valproic acid alone or in 
combination with dacarbazine plus interferon-α, VPA treatment did not result in 
superior results to standard therapy220. However, given the diversity of HDACi 
and their effects, these clinical results warrant further exploration of HDACi and 
HDACi combinations.  
A relatively new HDACi, LBH589 (panobinostat) has shown promise in the 
treatment of malignances. LBH589 is a hydroxamic pan-HDACi with nanomolar 
potency against all HDACs221. At low doses, LBH589 has proven to inhibit tumor 
growth in a variety of hematological and solid tumors including CTCL, CML, AML, 
Hodgkin lymphoma, breast, prostate, colon and pancreatic cancer221. Selectivity 
over normal cells has proven to be quite robust with values as high as 100x 
needed for toxicities in non-transformed cells. In line with other HDACi, LBH589 
has been shown to induce cell death pathways and block cell cycle 
progression222, as well as possessing anti-angiogenic properties199. Additionally, 
microarray of treated CTCL patient samples showed that sets of genes 
associated with immune regulation were altered in response to LBH589 
treatment223.  
Currently, LBH589 is at various stages of clinical trials for the treatment of 
various malignancies including: refractory chronic myelogenous leukemia, diffuse 
large B-cell lymphoma, pediatric hematological malignancies, recurrent glioma, 
high-grade meningioma, prostate cancer, acute myeloid leukemia, breast cancer, 
	  	   34	  
thyroid carcinoma, renal cell carcinoma, multiple myeloma, myelodysplastic, 
syndrome, non-small cell lung cancer, cutaneous T-cell lymphoma, colorectal 
cancer, liver cancer, mantle cell lymphoma, and small cell lung cancer224. 
Additionally, a phase I study of LBH589 in metastatic melanoma is currently 
active225.  
 
HDACs in T-cells 
 The role of individual HDACs in T-cells remains largely unexplored. Much 
of the current knowledge centers around the role of HDACs in regulatory T-cell 
(Treg) function.  
Of the individual HDACs, HDAC6 is currently the best studied. HDAC6 
has been shown to regulate Treg function, largely through HSP90. Initially it was 
found that HDAC6 is highly expressed in CD4+CD25+ T-cells compared to 
CD4+CD25- T-cells. This is true both in naïve and activated CD4+ T-cells. While 
HDAC6 knockout (HDAC6KO) CD4+ do not possess increased populations of 
CD4+foxp3+ T-cells, the Tregs from the HDAC6KO mice express more foxp3, IL-
10 and CTLA4 leading to greater suppressive activity in mixed lymphocyte 
reactions. Similar changes in suppressive molecule expression and suppression 
of effector T-cells is seen with treatment of the HDAC6 specific inhibitor tubacin. 
As HSP90 is a substrate for HDAC6 deacetylation, its role in the observed 
phenotypes was explored. To this end increased HSP90 acetylation as a result of 
decreased HDAC6 activity significantly contributes to the suppressive phenotype 
observed. Finally it was demonstrated that HDAC6 inhibition by tubacin is 
	  	   35	  
effective at preventing the development of colitis in dextran sodium sulfate 
induced mouse models226. A second known function of HDAC6 in T-cells is the 
regulation of the synapse of TCR-APC interaction. When the TCR of T-cells 
makes contact with APCs, a concentration of acetylated microtubules forms 
around CD3 and lymphocyte function-associated antigen 1 (LFA-1). Additionally, 
HDAC6 is also found concentrated at the contact site. When HDAC6 is 
overexpressed, the CD3 and LFA-1 becomes disrupted at the contact site and T-
cell activation is impaired227. It is worth noting that HDAC6 also has roles in TRL 
signaling via interactions with MyD88228 and cytokine signaling through regulation 
of JAK2214.  
Tregs also have elevated expression of HDAC9. Tregs from mice lacking 
HDAC9 have diminished suppressive activity in mixed lymphocyte reactions. 
Histochemical staining for HDAC9 shows that it was mainly located in the 
nucleus of Tregs, and after T-cell activation, HDAC9 localizes to the cytoplasm. 
The same study showed that treatment of Tregs with the HDACi TSA results in 
increased acetylation of foxp3, enhancing its ability to bind the IL-2 promoter. 
However, the role of HDAC9 in the acetylation of foxp3 remains unaddressed229. 
In a separate study, the same group further addressed the role of HDAC9 in a 
colitis mouse model. Using this model it was demonstrated that inhibition by pan 
but not class I specific HDACi results in increased numbers and suppressive 
function of Tregs, further resulting in decreased colitis severity. Severity of colitis 
is also associated with increased expression of HDAC9. Additionally, HDAC9KO 
mice are resistant to colitis and have increased expression of HSP70. 
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Immunoprecipitation experiments revealed that HSP70 interacts with foxp3. 
Finally, inhibition of HSP70 decreased the suppressive function of HDAC9KO 
Tregs230.  
HDAC7 is known to regulate double positive thymocyte survival. In double 
negative thymocytes, HDAC7 expression is low, but expression is dramatically 
increased upon further maturation to double positive.  Upon TCR engagement of 
double positive thymocytes, the predominately nuclear HDAC7 rapidly migrates 
to the cytoplasm. In single positive CD4+ thymocytes, expression of HDAC7 
remains cytoplasmic. While no differences in single positives are seen, 
conditional deletion of HDAC7 in thymocytes results in decreased populations of 
double positive and CD8+ and CD4+ single positive thymocytes. It was further 
noted that HDAC7KO thymocytes have increased apoptosis. This increased 
apoptosis is attributed to alteration of multiple products involved in the response 
to TCR engagement231.   
Finally, recently HDAC1 and HDAC2 were shown to be crucial for T-cell 
genome stability. Single knockouts of either HDAC1 or HDAC2 result in 
negligible effects on thymocyte cellularity, while a dual knockout drastically 
reduces cellularity. Double knockout also results in an arrest at the double 
negative to double positive transition. Gene expression analysis shows that 
expression of genes associated with TCR signaling are disrupted, suggesting 
that HDAC1 and HDAC2 are crucial for proper TCR signaling in thymocyte 
development232.  
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CHAPTER 2 
Utilizing the Pan-HDAC Inhibitor LBH589 as a Therapeutic Strategy to Inhibit 
Growth and Increase Immunogenicity in Melanoma 
 
Prelude and Rationale 
Metastatic melanoma is responsible for a majority of deaths from 
cutaneous malignancies. Furthermore individuals diagnosed with this disease 
face a 5-year survival of 15%. Unfortunately, few therapies exist which prolong 
survival for metastatic melanoma233.  Until recently, only two treatments were 
available for this deadly disease, dacarbazine and IL-2. More recently, 
vemurafenib and Ipilumumab have received FDA approval for the treatment of 
metastatic melanoma. Dacarbazine, a DNA alkylating agent, and vemurafenib, a 
tyrosine kinase inhibitor with efficacy in melanoma bearing a BRAF V600E 
mutation, target melanoma cells directly31. However, IL-2, a recombinant T-cell 
growth factor promoting T-cell activation, and Ipilumumab, a CTLA-4 blocking 
fully human antibody, target the patient’s immune response. 
Overcoming tolerance mechanisms and directing the immune response 
towards a pro-inflammatory response represent major hurdles in developing 
effective immunotherapy strategies against cancer. An important factor 
determining T-cell activation, and ultimately the type of immune response, is the 
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kind and quality of effector cell interactions with antigen presenting cells (APCs). 
Three signals between APCs and T-cells direct the ensuing immune response. 
These are 1) antigen in the context of MHC, 2) co-stimulatory molecules, and 3) 
cytokine signaling.  While classically associated with professional APCs (i.e. 
macrophages, dendritic cells, and B-cells), other somatic cells can function as 
non-professional APCs. Indeed, it has become increasingly evident that tumor 
cells harbor APC-like functions234-236. However, it is likely that this potential 
function is negatively affected by the immunosuppressive microenvironment that 
characterizes the tumor site, through the expression of inhibitory ligands such as 
PD-L1 and/or production of anti-inflammatory cytokines such as IL-10, VEGF or 
TGF- β 237,238. Therefore, strategies that are able to alter the tumor 
microenvironment by tempering an anti-inflammatory, while enhancing a pro-
inflammatory phenotype, may provide for more effective anti-tumor immunity.   
HDAC inhibitors (HDACi) have demonstrated selective anti-proliferative 
properties and cytotoxicity to tumor cells compared with minimal effects on 
normal cells 239,240. Indeed, two HDACi have already been approved for the 
treatment of patients with refractory cutaneous T-cell lymphoma 241. However, 
their therapeutic efficacy in solid malignancies including melanoma remains to be 
fully explored. In addition to their direct cytotoxic effects, there is growing 
evidence supporting previously unknown immunoregulatory properties of HDACi.  
In the context of melanoma, studies have already demonstrated clear 
immunoregulatory effects of these compounds. For instance, Khan et al. 
demonstrated up-regulation of MHC I and CD86 molecules on melanoma cells 
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treated with pan-HDACi.  This resulted in tumor cells that were better able to 
activate antigen-specific T-cells in vitro 242. Furthermore, Vo et al. reported 
treating mice bearing B16 melanoma tumors with the HDACi LAQ824 either 
alone or in the setting of adoptive T-cell immunotherapy243. In these experiments, 
combined HDAC inhibition and adoptive cell therapy resulted in prolonged 
survival of melanoma bearing mice.  Mechanistically, HDACi treatment promoted 
the expansion and persistence of the adoptively transferred antigen specific T-
cells 
Therefore, this study sought to characterize the effects of the pan-HDACi 
LBH589, currently in phase III clinical trials for patients with multiple myeloma, to 
further assess its therapeutic potential for the treatment of melanoma, Herein its 
direct anti-tumor effects in addition to its ability to modulate tumor 
immunogenicity were evaluated. 
 
Materials and Methods 
 
Cell Lines 
Melanoma cell lines were obtained from the ATCC and cultured in RPMI 
1640 supplemented with 10% FBS, 100U/mL penicillin, 100µg/mL streptomycin  
and non-essential amino acids (herein referred to as complete RPMI). The 
luciferase and CCR7 expressing B16 (CCR7-luc-B16) was provided by Sam 
Hwang244. CCR7-luc-B16 cells were grown in complete RPMI containing 1mg/mL 
G148 and 2ug/mL puromycin selective additives. The human melanocyte cell 
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line, HEMn-LP, was obtained from Invitrogen (Carlsbad, CA) and grown in 
manufacturer suggested media, Medium 254 supplemented with HMGS. All cell 
lines were grown under humidified conditions at 37ºC and 5% CO2.  
 
HDACi 
MGCD0103 was purchased from Selleck Chemicals (Houston, TX), and 
Trichostatin A (TSA) from Sigma Aldrich (St. Louis, MO). LBH589 was kindly 
provided by Novartis (Basel, Switzerland). For in vitro use, LBH589 was 
reconstituted in DMSO at greater than 1000x the final effective dose and stored 
in aliquots at -80ºC. HDACi stocks were diluted in complete medium immediately 
prior to use. For in vivo studies, LBH589 was dissolved in a 5% dextrose solution 
and sonicated to aide dissolution. 
 
Mice 
Wild-type C57BL/6, were purchased from NCI laboratories. Transgenic 
OTII and B6.129S7-Rag1tm1Mom/J immunodeficient mice were purchased from 
Jackson laboratories. All animals were housed and studies performed in 
compliance with protocols approved by the IACUC at the University of South 
Florida. 
 
Melanoma In Vivo 
For in vivo tumor studies, mice were injected subcutaneously into the 
shaved flank with 100,000 B16 or 50,000 CCR7-luc-B16 melanoma cells 
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suspended in 100µL Hank’s Balanced Salt Solution (Invitrogen). Treatments 
began at the time that tumors were palpable in the majority of mice.  
 
In Vivo Imaging 
For in vivo imaging of tumor burden using CCR7-luc-B16 cells, an 
PerkinsElmer (Waltham, MA) IVIS Lumina Series II imager was used. Mice were 
intraperitoneally injected with 200uL of luciferin dissolved in sterile PBS at a 
concentration of 15mg/mL. Mice were then anesthetized using isoflurane and 
imaged 10 minutes post injection. Living Image In Vivo Imagine software was 
used to analyze resulting data.  
 
Determining IC50 by MTS 
To determine growth inhibition, cells were plated at 5x103/well in 96-well 
flat bottom plates.  The following day, media was changed to that containing 
LBH589 or DMSO vehicle diluted in complete medium.  Cells were incubated for 
72 hours at 37ºC and 5% CO2.  Density of viable, metabolically active cells was 
quantified using a standard MTS assay purchased from Promega (Fitchburg, WI) 
as per manufacturer’s instructions.  Briefly, 20µL of reagent were added per well 
and incubated at 37ºC for up to three hours. Absorbance at 490nM was 
measured spectrophotometrically with background subtraction at 670nM.  All 
values were then normalized and expressed as a percentage of DMSO control 
growth.  
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Determination of Apoptosis 
For apoptosis analysis, melanoma cells treated with LBH589 or DMSO for 
48 hours and were detached by brief AccutaseTM (Invitrogen) treatment. Cells 
were then washed and stained with Annexin V according to the manufacturer’s 
(BD Biosciences) protocol. Briefly, cells were washed twice with cold PBS, then 
stained with FITC conjugated Annexin V concomitantly with propidium iodide (PI) 
viability staining. Data was collected using an LSR II flow cytometer and 
analyzed using FlowJo software.  
 
Cell Cycle Analysis 
For cell cycle analysis, melanoma cells were treated with indicated doses 
of LBH589 or DMSO control for 48 hours. Cells were washed and resuspended 
in 75% ethanol overnight to permeabilize and fix. Samples were then washed 
and resuspended in PBS containing 0.1% Triton X-100. Finally, samples were 
treated with RNAse A, stained with PI, and data was acquired using a FACScan 
(BD Biosciences) flow cytometer. Data analysis was performed using FlowJo 
software.  
 
Western Blot Analysis 
Lysis buffer containing 1% SDS + 4M Urea + 100mM dithiothrietol in 
100mM Tris was used to completely lyse cells.  Lysates were sonicated on ice for 
16 minutes in pulses of 30 seconds on, 30 seconds off. Cell lysates were stored 
at -80ºC until analyzed by western blot. Lysates were mixed 5:1 with a 6x gel 
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loading buffer (0.2% (w/v) bromophenol blue + 200mM DTT + 20% Glycerol) and 
boiled for 15 minutes. Samples were then resolved on a SDS-PAGE gel and then 
transferred to nitrocellulose membranes. These were then immunoblotted against 
respective antigens. Anti-GAPDH antibody was purchased from Sigma Aldrich 
(St. Louis, MO). Anti-PARP antibody was purchased from Cell Signaling 
(Beverly, MA). Blots were then incubated with appropriate IRDYE secondary 
antibody and developed using a LI-COR developer. 
 
Cell Surface Marker Expression 
For surface marker analysis, melanoma cells were treated with LBH589 or 
DMSO for 48 hours, and then briefly trypsinized to form a single cell suspension. 
Cells were then washed and resuspended in MACS (DPBS + 2mM EDTA + 2% 
FBS) buffer. Cells were stained with phycoerythryn (PE), fluorescein 
isothiocyanate (FITC) or allophycocyanin (APC) conjugated antibodies against 
MHC I, MHC II, CD40, CD80, or CD86. Conjugated antibodies were purchased 
from eBioscience (San Diego, CA). After staining for 20 minutes at 4ºC, cells 
were washed three times and then resuspended in buffer containing DAPI 
(50ng/mL) for viability. A minimum of 10,000 events were collected using an LSR 
II (BD Biosciences, Franklin Lakes, NJ) flow cytometer and subsequently 
analyzed using FlowJo software. 
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Antigen Specific T-cell Activation  
B16 melanoma cells were treated with indicated doses of LBH589 or 
DMSO for 48 hours. Cells were then washed with media and subsequently 
ovalbumin (OVA) specific antigen specific CD4+ T-cells (OTII) plus OVA peptide 
(Ile-Ser-Gln-Ala-Val-His-Ala-Ala-His-Ala-Glu-Ile-Asn-Glu-Ala-Gly-Arg) were 
added to the melanoma culture.  Twenty-four hours later, supernatant was 
collected and assessed for cytokine production by a standard ELISA protocol. 
 
Quantitative Reverse Transcriptase PCR 
Cells were plated overnight then treated for 24 hours with LBH589 or 
DMSO. Cells were then lysed using TRIzol® from Invitrogen. RNA was isolated 
using a standard phenol-chloroform separation protocol, and cDNA generated 
using iScript™ from Bio-Rad (Hercules, CA). Expression was assessed by qRT-
PCR using a SYBR Green system. Primers for human GAPDH (forward: 
GAAGGTCGGAGTCAACGGATT, reverse: ATGGGTGGAATCATATTGGAAC) 
and mouse 18s ribosomal RNA from Qiagen (Shanghai, China) were used for 
reference genes. Primers for human gp100 (forward: 
TGGAGAGGTGGTCAAGTGTC , reverse: TGGCAATACCTTTTGGCTTC), mart1 
(forward: AAGGAAGGTGTCCTGTGCC, reverse: 
TCAGCCGTGGTGTAAGAGTG), tyrp1 (forward: GACATGCAGGAAATGTTGC, 
reverse: CATCAAGTCATCCGTGCAGA), and tyrp2 (forward: 
GCAAGTGCACAGGAAACTTTG, reverse: CCGAATCACTGGTGGTTTCT) were 
utilized for WM793 cells. Primers for mouse gp100 (forward: 
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CATCAATGGGAGCCAGGTG, reverse: TTCGGAGGTTTAGGACCAGA), mart1 
(forward: GGAAGGTGTCCTGTGCTGA, reverse: 
TGACATAGGAGCGTCTGTGC), tyrp1 (forward: 
GCAGCTCTGTGCTGTATTTTCA, reverse: GGGGGAGGACGTTGTAAGAT), 
and tyrp2 (forward: GTGCGACAGCTTGGATGACTA, reverse: 
CAGGCAATCTTGCACATTTTT) were utilized for B16 cells.  
 
Macrophage Cytokine Production 
Peritoneal exudate macrophages (PEMs) were generated by i.p. injection 
of 1mL thioglycollate into wild-type mice. Four days following, PEMS were 
isolated by peritoneal lavage. PEMs (1x105) were activated with 2µg/mL 
lipopolysaccharide (LPS) in the presence of absence of LBH589 for 24 hours. 
Cells were then washed and co-cultured in the presence of HA peptide 
(SFERFEIFPKE) with 5x104 naïve CD4+ T-cells isolated from HA TCR-
transgenic mice. After 48 hours supernatants were collected and analyzed for 
cytokine production by ELISA.  
  
T-cell Cytokine Production 
 T-cells were isolated from wild-type C57BL/6 mice using a CD3+ negative 
selection kit from Stemcell Technologies (Vancouver, Canada). Cells were 
cultured in complete RPMI supplemented with 50µM 2-mercaptoethanol. Cells 
were then treated with indicated dose of LBH589 or DMSO and concomitantly 
activated with a 1:1 ratio of αCD3/CD28 Dynabeads® (Invitrogen) for 72 hours. 
	  	   46	  
Supernatants were collected and stored at -80°C until analyzed. Cytokine 
production was analyzed by a cytokine bead array (BD Biosciences) using a 
FACS Calibur and analyzed by FCAP software (BD Biosciences).  
 
Determination of T-cell Viability 
T-cells were isolated from wild-type C57BL/6 mice using a CD3+ negative 
selection kit from Stemcell Technologies. Cells were cultured in complete RPMI 
supplemented with 50µM 2-mercaptoethanol. Cells were then treated with 
indicated dose of LBH589 or DMSO and concomitantly activated with 
αCD3/CD28 Dynabeads® (Invitrogen) at a 1:1 ratio for 72 hours. Cells were 
washed and stained with 50ng/mL of DAPI. Viability was analyzed on an LSRII 
flow cytometer (BD Biosciences) and analyzed by FlowJo software.  
 
Statistical Analysis 
Significance of melanoma growth inhibition, T-cell cytokine production, 
and T-cell viability was determined by one-way ANOVA using GraphPad Prism 
5.0 software. In addition, GraphPad Prism 5.0 software was used to determine 
significance of survival curves. Values of p<0.05 were considered significant. 
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Results 
 
HDAC Inhibitors have Direct Anti-Melanoma Activity In Vitro 
Given the previously reported anti-tumor activity of HDACi 245,246, initially 
the direct anti-melanoma efficacy of various HDACi was determined. As shown in 
Figure 1A, the pan-HDAC inhibitors LBH589 and TSA in addition to the class 1 
specific HDACi MGCD0103 inhibited the growth of murine melanoma B16 and 
two human melanoma lines, WM793 and WM983A. LBH589 had a particularly 
potent effect on melanoma growth with IC50 values in the low nanomolar range.  
To further assess the anti-melanoma activity of LBH589, its effects on 
additional human melanoma cell lines were assessed in vitro. All treated cell 
lines displayed significant, dose-dependent, impairment in growth (Figure 1B). 
IC50 values ranged from 25nM to 100nM. Importantly, LBH589 inhibited the 
growth of human melanoma cells with different genotypic and phenotypic 
characteristics such as cell lines with BRAF mutations (WM793, WM983A, 
WM35 and WM164), melanoma cells with constitutively activated STAT3 
(WM793) and the CDKN2A mutant cell line SKMEL21247. A dose dependent 
inhibition in cell growth was observed in all these cell lines, with minor differences 
in sensitivity.  
To determine the selectivity of LBH589 to transformed cells, cell growth 
inhibition was also assessed in a non-transformed, human melanocyte cell line. 
As shown in Figure 1B (open squares) at the concentrations used, no impairment 
in the growth of normal melanocytes was observed.  
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To mechanistically dissect the inhibitory effect of LBH589, two known 
effects of HDACi, cell death and cell cycle arrest181,245,248-251 were investigated. 
Measurement of viability (propidium iodide) and surface expression of 
phosphatidylserine (Annexin V) by flow cytometry evidenced a marked increase 
in cellular death in the three cell lines analyzed at both concentrations assessed 
Figure 1. LBH589 is a potent inhibitor of melanoma cell growth in vitro. (A) Two 
human (WM793 and WM983A) and one murine (B16) melanoma cell lines were 
plated in triplicate and treated for 72 hours with indicated doses of LBH589 (black), 
TSA (diagonal striped), MGCD0103 (horizontal striped) or DMSO control (white). An 
MTS assay to determine relative amounts of metabolically active cells was 
performed. Values were converted to a percentage of DMSO treatment growth for 
each cell line. Means +/- SEM were graphed and doses compared to DMSO control 
(***p<0.001). (B) Indicated melanoma cell lines, along with the human melanocyte 
cell line HEMn-LP, were plated in triplicate and treated for 72 hours with LBH589. 
Using an MTS assay, dose response curves were generated.  
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(Fig 2A). Induction of apoptosis was further confirmed by analysis of PARP 
cleavage (Fig 2B). To investigate any potential cell cycle inhibitory effects of 
LBH589, propidium iodide staining of DNA in fixed cells 48-hours post LBH589 
treatment was used to determine cell cycle distribution. Consistent with previous 
reports of HDACi anti-tumor effects in other malignancies252-254, LBH589 induced 
a G1 cell cycle arrest in melanoma lines WM793 and WM983A (Figure 2C). 
Additionally, a G2 arrest is apparent in WM983A, but not WM793 cells.  
 
 
 
 
Figure 2. LBH589 induces both apoptosis and a G1 cell cycle arrest in 
melanoma cells.  Indicated melanoma cell lines were plated overnight. The following 
day, cells were treated with indicated concentrations of LBH589 or equivalent volume 
of DMSO for 48 hours. (A) Cells were assessed for viability and 
phosphatidylserine translocation by means of propidium iodide and annexin V 
staining respectively and analyzed by flow cytometry. (B) Cleaved PARP levels were 
measured by protein immunoblotting. (C) Cell cycle distribution of cells was 
determined by propidium iodide staining of fixed cells. Analysis and percent 
distributions were determined using FlowJo software.  DMSO treatment is shown in 
black, 25nM LBH589 in blue, and 50nM in red.  
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LBH589 Augmented Expression of Immunologically Relevant Molecules in 
Melanoma Cells, Enhancing T-cell Sctivation 
Previous reports have suggested an immunologic effect of HDACi on 
tumor cells255.  To address this question, melanomas were stained for various 
immunologically relevant molecules. In B16 cells LBH589 treatment resulted in 
upregulation of MHC class I, MHC class II as well as the costimulatory molecules 
CD40, CD80 and modest upregulation of CD86 (Figure 3A, row 1). In WM793 
LBH589 treatment resulted in similar upregulation of MHC class I and class II. 
However, while modest upregulation of CD40 and CD86 were noted, no 
differences in CD80 were seen (Figure 3A, row 2). As well, in WM983A 
upregulation of MHC class I was seen, but no changes in class II were observed. 
Increases in CD40 and CD86 expression were also seen, but no alterations were 
seen in CD80 levels (Figure 3A, row 3).  
Next, it was determined whether this enhanced expression of 
immunologically relevant molecules rendered melanoma cells better able to 
activate antigen-specific T-cells. To answer this question B16 murine melanoma 
cells (H-2b) were treated with LBH589 and then cultured with OVA-specific CD4+ 
T-cells (OT-II) with or without the presence of cognate OVA-peptide.  As shown 
in Figure 3B, CD4+ T-cells encountering cognate peptide on LBH589-treated B16 
cells produced significantly higher levels of both IL-2 and IFN-γ as compared to 
T-cells encountering antigen in untreated or DMSO treated melanoma cells.  
While enhanced expression of costimulatory molecules and MHC 
molecules can aid in directing the type and magnitude of the immune response, 
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recognition of tumor by T-cells is essential to generating an anti-tumor immune 
response. Consequently, the expression of several melanoma differentiation 
antigens in LBH589 treated melanoma was analyzed. As shown in figure 3C, 
treatment with LBH589 results in enhanced expression of gp100, mart1, tyrp1 
and tyrp2 in both B16 and WM793 cells. 
 
LBH589 Enhances the Pro-Inflammatory Phenotype of Immune Cells 
 
 As LBH589 is administered systemically, it was important to determine the 
direct effects of LBH589 on immune cells. To this end, peritoneal exudate 
macrophages (PEMs) were activated with LPS, treated with LBH589 and co-
cultured with HA antigen specific CD4+ T-cells in the presence of HA antigen. 
LBH589 treatment of PEMs resulted in a dose dependent increase in IL-2 (Figure 
4A) and IFN-γ (Figure 4B) production by T-cells, indicative of an enhanced type 1 
activation by the macrophages. Additionally, the effects of treating CD3+ T-cells 
directly with LBH589 were investigated. T-cells activated non-specifically through 
CD3/CD28 ligation concomitantly with LBH589 treatment produced profoundly 
higher amounts of IFN-γ (Figure 4C). However, this was also accompanied by a 
significant decrease in T-cell viability (Figure 4D).  
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Figure 3. LBH589 increases the immunogenicity of melanoma. (A) Indicated 
melanoma cell lines were plated overnight. The following day, cells were treated with 
50nM LBH589 or equivalent volume of DMSO for 48 hours. Cells were assessed by 
flow cytometry for expression of indicated surface markers. Expression levels of 
DMSO treated cells are shown in grey outline, treatment with 50nM LBH589 is shown 
in black outline and unstained auto-florescence is shown in solid grey. Data shown 
are representative of results from three independent experiments. (B) B16 cells were 
treated with LBH589 for 48 hours. Cells were washed, then irradiated, loaded with 
ovalbumin peptide and plated with OTII T-cells for 24 hours. Supernatant was 
collected and analyzed by ELISA for IFN-γ and IL-2 production. Cytokine levels are 
compared against DMSO treatment group (**p<0.01, ***p<0.001). (C) B16 and 
WM793 cells were plated overnight, then treated for 24 hours with indicated doses of 
LBH589 or DMSO. Expression of mRNA for indicated melanoma antigens was 
assessed by qRT-PCR. Data shown are representative of results from three 
independent experiments. 
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The In Vivo Anti-Melanoma Efficacy of LBH589 Requires an Intact Adaptive 
Immune System 
Given these effects of LBH589 in vitro on melanoma cells, it was assessed 
whether this would translate to a relevant anti-melanoma effect in vivo. Thus, 
C57BL/6 mice were challenged with B16 melanoma cells injected 
subcutaneously. When tumors became palpable (>3mm), melanoma bearing 
mice were randomly assigned to receive either 5% dextrose in PBS vehicle 
Figure 4. LBH589 treatment of immune cells enhances pro-inflammatory 
function. Murine PEMs were treated with LPS and LBH589 for 24 hours, and 
subsequently co-cultured with antigen specific CD4+ T-cells and their cognate 
antigen for 48 hours. T-cell cytokine production was assessed by ELISA (A,B). CD3+ 
T-cells were activated in the presence of indicated doses of LBH589 or DMSO for 72 
hours. Cytokine production was assessed by cytokine bead array (C) and viability by 
DAPI staining (D). **p<0.01, ***p<0.001.  
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control, or LBH589 (25mg/kg), each administered three times weekly by 
intraperitoneal (ip) injection. As shown in Figure 5A, a significant increase in 
survival was observed in those mice treated with LBH589. Additionally, 
administration of 15mg/kg of LBH589 results in a significant decrease in tumor 
progression in WT mice (Figure 5C). In a similar, but independent experiment 
using CCR7-luc-B16, a notable decrease in metabolically active tumor was seen 
in LBH589 treated mice (Figure 5D).  
The survival advantage observed in LBH589-treated melanoma bearing 
mice could be a reflection of its direct effect upon tumor cells and/or its effects 
upon melanoma immunogenicity and the host antitumor immune response. To 
address the contribution of these two factors to the observed in vivo outcomes, 
C57BL/6 SCID mice, lacking T and B-cells, were challenged with B16 melanoma 
cells injected subcutaneously. When tumors became palpable, melanoma-
bearing mice were randomly assigned to LBH589 treatment or vehicle control 
groups. Unlike immunocompetent melanoma bearing mice treated with LBH589, 
in which a significant survival advantage was demonstrated, such an effect was 
not observed in immunodeficient animals treated with LBH589 (Figure 5B).  
These results indicate that the antitumor effect of LBH589 required an intact 
adaptive immune system and points to the immunological anti-tumor effects 
triggered by LBH589 as playing a dominant role in its in vivo anti-melanoma 
activity.  
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Discussion 
This study describes a multi-fronted anti-melanoma effect of the HDAC 
inhibitor LBH589 through direct cytotoxicity and augmentation of anti-tumor 
immunogenicity, as well as enhancement of the pro-inflammatory immune 
response by APCs and T-cells. Overall, the effects can be broken down into two 
Figure 5. In vivo, LBH589 administration prolongs survival in 
immunocompetent, but not immunodeficient, melanoma bearing mice. C57BL6 
mice (A,C,D) or immunodeficient B6.129S7-Rag1tm1Mom/J (D) were injected 
subcutaneously with B16 melanoma (A,B,C) or CCR7-luc-B16 (D). Ten days 
following inoculation, tumors were visible and treatment with 25mg/kg (A,B), 15mg/kg 
(C,D) LBH589 or dextrose vehicle control commenced. Treatment was administered 
three times weekly by intraperitoneal injection. Animals were imaged for metabolically 
active tumor cells on day 29 (D). *p<0.05. 
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main categories: direct melanoma cytotoxcitiy and enhancement of the anti-
tumor immune response. The direct cytotoxic effects of LBH589 are mediated by 
induction of G1 cell cycle arrest and apoptosis of melanoma cells. Intriguingly, as 
seen in WM983A, LBH589 also is capable of inducing a G2 arrest in some 
melanomas. While G2 arrests are less common in HDAC inhibitor treated cells 
than G1 arrests, such arrests are known to occur256. Melanoma cell lines are 
highly heterogeneous41, and it is likely that mutational differences in WM983A 
cells result in this G2 arrest. Future work is needed to test this hypothesis.  
The immunological effects of LBH589 demonstrated here are diverse and  
include: 1) augmentation of the APC function of melanoma cells through up-
regulation of immune-relevant receptors/ligands, 2) amplified expression of 
melanoma differentiation antigens, 3) increased activation of antigen specific T-
cells, 4) enhancement of pro-inflammatory activation of T-cells by macrophages, 
and 5) enhanced IFN-γ production by activated T-cells. This repertoire of in vitro 
properties translate into positive in vivo effects, where LBH589 produced a 
significant increase in survival in melanoma bearing mice, an effect that is 
dependent on intact adaptive immunity.  
In the past several years, a number of therapeutic approaches have 
sought to improve the weak antigen-presenting capabilities of solid tumors by 
either genetically modifying these cells to enforce the expression of 
adhesion/costimulatory molecules257,258 or by using cytokines such as IFNs to 
upregulate the expression of MHC molecules in tumor cells in vivo 259.  Although 
these approaches generate productive immune responses, the duration and 
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magnitude of these effects is transient and not strong enough to eradicate solid 
malignancies.  It is plausible that the strong immunosuppressive 
microenvironment that characterizes the growth of solid tumors, through the 
expression of inhibitory ligands such as PD-L1 and/or production of anti-
inflammatory cytokines such as IL-10, VEGF or TGF-β impose a barrier too 
difficult to overcome by this earlier generation of immunotherapeutic approaches. 
Novel therapies endowed with the dual ability to influence tumor growth as well 
as its immunogenicity might be more successful in triggering durable antitumor 
immune response against solid malignancies, including metastatic melanoma. 
For instance, recent studies have shown that the coupling of tumor cell death 
with elicitation of inflammatory responses, a process also known as 
“inflammatory death”, resulted in more potent and long lasting anti-melanoma 
immunity 260. 
Previously the Sotomayor lab has demonstrated that the pan-HDACi 
LAQ824, which belongs to the same family of hydroxamic acid derivatives as 
LBH589, augments the expression of MHC and costimulatory molecules in 
professional APCs by inhibiting the production of the immunosuppressive 
cytokine IL-10 and by increasing the production of several pro-inflammatory 
mediators. Such an effect resulted in the generation of inflammatory APCs that 
effectively activate antigen-specific CD4+ T-cells and restore the responsiveness 
of anergic T-cells. The same study also showed similar results for LBH589. 
PEMs treated with LBH589 and activated with LPS produced significantly more 
IL-12 and less IL-10 in a dose dependent manner261. As shown here, the positive 
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immunological effects triggered by this family of HDAC inhibitors is not limited to 
professional APCs, since treatment of melanoma cells (non-professional APCs) 
with LBH589 also resulted in increased immunogenicity and effective T-cell 
activation. However, it remains to be determined whether the changes observed 
in LBH589-treated melanoma cells involved the same mechanism(s) identified in 
professional APCs. Some evidence presented here point to some mechanistic 
differences. For instance, in APCs treated with LBH589 a consistent upregulation 
of MHC and B7.2 costimulatory molecules is observed. This effect is however not 
always seen in human melanoma cells lines. It is possible that alternate 
epigenetic mechanisms are responsible for silencing CD86 in human melanoma 
cells, which might not be solely reverted by HDAC inhibition.   
In addition to effects on tumor cells, direct treatment of concomitantly 
activated T-cells with LBH589 resulted in profound enhancement of IFN-γ 
production. Intriguingly, this result is in contrast to previous reports of HDACi 
effects on T-cells. Indeed, treatment of T-cells with the pan-HDACi trichostatin A, 
was previously shown to dramatically decrease production of IFN-γ215. Similarly, 
scriptaid and sodium butylate have also been demonstrated to decrease IFN-γ 
production by T-cells218. While LBH589 generated robust production of IFN-γ in 
T-cells, it must be noted that LBH589 also resulted in substantial reduction in T-
cell viability. As recent report has demonstrated that HDAC1/2 are essential to 
the genomic stability of T-cells232, the inhibition of these HDACs by LBH589 may, 
at least in part, explain the decrease in viability seen, though future experiments 
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are needed to validate this hypothesis.  As such, these results exemplify the 
need for understanding the role of individual HDACs in T-cells.  
This demonstration that LBH589 is an effective therapeutic strategy in a 
murine model of melanoma provides the basis for evaluating the efficacy of this 
compound in human melanoma. The additional demonstration of aberrant 
expression of several HDACs in human melanoma cells 262-265 provides further 
support for the evaluation of the therapeutic efficacy of LBH589 in this disease. 
Compared to LAQ824, for which clinical development was stopped, LBH589 has 
a better safety profile. An additional advantage of LBH589 is that it is an oral 
agent. These properties have led to the clinical development of LBH589, which is 
currently undergoing evaluation in a phase III clinical trial for patients with 
multiple myeloma.  
The previously unknown, multifaceted, positive effects of LBH589 upon 
melanoma cells, coupled with the pro-inflammatory enhancement of immune cell 
response, and together with our recent findings confirming that LBH589 is more 
potent than LAQ824 in inhibiting melanoma cell proliferation (data not shown), 
provide the framework for the future evaluation of LBH589 in combination with 
other immunomodulatory agents such as ipilimumab in human metastatic 
melanoma. 
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CHAPTER 3 
Elucidating the Roles of Histone Deacetylases 11 in T-cells 
 
Prelude and Rationale 
T-cells are of critical importance in the immune system’s ability to clear 
transformed cells, including virally infected and neoplastic cells. Indeed, in the 
setting of cancer, T-cells represent one of the main effector cell types responsible 
for destruction of malignant cells. In malignancies such as melanoma, the degree 
of tumor infiltrating lymphocytes (TILs) is correlated with duration of patient 
survival76. However, in order for T-cells to mount an effective response against 
malignant cells, a number of criteria must be met, including recognition of antigen, 
proper co-stimulation, and pro-inflammatory polarization by cytokines in the 
surrounding microenvironment. Failure in any one of these requirements is likely 
to result in tolerance in lieu of clearance of the tumor.  
The existence of tumor antigens that T-cells are capable of recognizing 
and mounting a response against has been known for nearly half a century266. 
However, any cancer observed in the clinical setting has escaped immune 
destruction. This escape is known to occur through a variety of mechanism 
including expression of co-inhibitory molecules (e.g. PDL1), production of anti-
inflammatory cytokines (e.g. IL-10), or recruitment of suppressive cell types (e.g. 
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Tregs)83,105,106. Additionally, chronic antigen exposure, as is the case in cancers, 
often leads to T-cell exhaustion267. T-cell exhaustion is a dysfunctional state in 
which T-cells have impaired effector functions and is characterized by expression 
of inhibitory receptors and exhaustion markers such as PD1 and Tim-3268. 
Adoptive T-cell therapy has demonstrated efficacy in the treatment of 
malignancies126. The process of adoptive immunotherapy involves the ex vivo 
identification and expansion of autologous tumor antigen specific T-cells. These 
cells are then transferred back into patients. One of the key factors mediating the 
success of adoptive T-cell therapy is persistence of infused lymphocytes269. 
Attempts to improve upon traditional adoptive T-cell therapy through the use of 
engineered TCR and CAR technology have shown mixed results. For example 
use of either of these technologies results in a limited ability to respond to 
antigen. This creates a selective pressure on the tumor often resulting in 
elimination of the antigen expressing population and expansion of a non-
expressing population126. Additionally, these techniques require the identification 
of antigens to generate TCR or CARs against. Therefore, novel strategies that 
improve the effectiveness of traditional adoptive transfer techniques are needed.  
Histone acetylation status represents a major mode of epigenetic 
regulation. Two classes of enzymes are known to work in opposition to regulate 
the chromatin state through acetylation: histone acetyltransferases (HATs) and 
histone deacetylases (HDACs). As their name implies, HDACs are a class of 
enzymes named for the observation of their involvement in removing acetyl 
groups from histone lysine residues. In humans, HDACs are grouped by their 
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phylogenetic relatedness and sequence homology into four main classes: class I 
(HDAC1, HDAC2, HDAC3, HDAC8), class II (HDAC4, HDAC5, HDAC7, HDAC9, 
HDAC6, HDAC10), class III (sir2-like or sirtuin proteins), and class IV 
(HDAC11)135. First identified in 2002, compared to the other HDACs, relatively 
little is known about HDAC11. In regards to immune function, has been shown to 
negatively regulate IL-10270 and PAI-1144 expression in APCs. Additionally, 
HDAC11 has been shown to regulate OX40L expression in Hodgkin lymphoma 
cells271.   
Until recently, remarkably little was known of the roles that individual 
HDACs play in T-cell biology. HDAC6 and HDAC9 both have been linked to Treg  
function226,229,230. HDAC6 also regulates the synapse in T-cells that occurs during 
TCR-APC interaction (226). As well, HDAC7 appears to regulate survival of 
double positive thymocytes during positive selection. Finally, HDAC1 and HDAC2 
have recently been shown to be essential for genome stability in T-cells.  
 Given the lack of published data on the role of individual HDACs in T-cells, 
the role of the newest HDAC, HDAC11, was explored in T-cells. To this end it 
was found that HDAC11 is highly expressed in naïve T-cells, with differences in 
expression levels based on thymocyte developmental stages, memory subsets,  
and activation status. Furthermore, T-cells lacking HDAC11 have enhanced 
effector functions and are resistant to anergy formation and Treg suppression. In 
vivo, T-cells lacking HDAC11 mediate a more potent and robust graft-vs-host 
disease (GvHD) in addition to being better able to control tumor growth in an 
adoptive transfer model of melanoma. In an attempt to mechanistically dissect 
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the cause of this phenotype, it is shown that T-cells lacking HDAC11 have 
normal TCR components and signaling response, but express higher levels of 
the transcription factors eomes and T-bet.   
 
Materials and Methods 
 
Mice 
Transgenic OTI and OTII were purchased from Jackson laboratories.  
eGFP-HDAC11 reporter mice were provided by Nathaniel Heintz through the 
Mutant Mouse Regional Resource Centers272. Histone deacetylase 11 knockout 
(HDAC11KO) mice were provided by Merck Research Laboratories. HDAC11KO 
mice are on a C57BL/6 background, and were generated by a targeted deletion 
of exon three of the HDAC11 gene utilizing cre-recombinase expression driven 
by the ubiquitously expressed Rosa26 promoter. OTI and OTII mice were bred 
with HDAC11KO mice to generate the OTI/HDAC11KO and OTII/HDAC11KO 
mice strains. Genotyping of HDAC11KO mice was performed by overnight 
digestion of tail snips, and subsequent isolation of DNA. DNA was quantified 
using a Nanodrop system and 50ng of DNA was utilized in a PCR reaction. 
Primer sequences are as follows: Set 1) Forward: 
CCTTGGAATAGCATCTCAGG, Reverse: TGCTGCCTGTGAGCCACTGC. Set 
2) Forward: AGAATGGCTGTCTCCCTAGG, Reverse: 
TGCTGCCTGTGAGCCACTGC. Product bands were resolved by gel 
electrophoresis on a ethidium bromide containing 1.5% acrylamide gel. All animal 
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were housed in compliance with protocols approved by the IACUC at the 
University of South Florida.  
 
Primary Cells and Cell Lines 
Primary mouse T-cells were obtained from mouse organs by physical 
digestion and straining through a 70µm filter. For isolates from mouse spleens or 
peripheral blood, red blood cells were lysed by a three-minute incubation in a 2:1 
ratio of ACK lysis buffer (Invitrogen) to PBS. Cells were subsequently washed 
twice with PBS. CD3+, CD4+, or CD8+ T-cells were further isolated by use of the 
appropriate negative magnetic separation kit from StemCell Technologies 
(Vancouver, Canada). Human T-cells were obtained from healthy human donor 
samples provided by Florida Blood Services. Buffy coats were isolated from 
whole blood by a standard Ficoll separation protocol. CD3+ T-cells were further 
isolated by use of the appropriate negative magnetic separation kit from 
StemCell Technologies. 
Primary mouse and human T-cells were cultured in complete RPMI 
supplemented with 10% FBS, 100U/mL penicillin, 100µg/mL streptomycin,  non-
essential amino acids and 50µM 2-mercaptoethanol (hereto referred to as T-cell 
media). Mouse spleenocytes were isolated from harvested mouse spleens, 
washed with PBS and suspended in RPMI 1640 media supplemented with 10% 
FBS, 100U/mL penicillin, 100µg/mL streptomycin and non-essential amino acids. 
Cells were cultured at 37ºC and 5% CO2 overnight. Nonadherent cells were 
washed off with two washes of PBS. B16 murine melanoma cells were obtained 
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from the ATCC and cultured in RPMI 1640 supplemented with 10% FBS, 
100U/mL penicillin, 100µg/mL streptomycin and non-essential amino acids. All 
cell lines were grown under humidified conditions at 37ºC and 5% CO2.  
 
Western Blots 
T-cells were isolated from WT or HDAC11KO mice and activated with 
CD3/CD28 stimulation for indicated amounts of time. Cells were lysed with buffer 
containing containing 50mM tris-HCl (pH 7.4), 150mM NaCl, 2mM MgCl2, 10% 
glycerol, and 1% NP-40 supplemented with 2mM Na3VO4, 1mM 
phenylmethylsulfonyl fluoride (PMSF) and Protease Inhibitor Cocktail (Sigma). 
Lysates were separated by SDS-PAGE and blotted with indicated antibodies.  
 
Quantitative RT-PCR 
RNA was extracted from cells using Trizol as per manufacturer’s 
instructions. Samples were processed immediately or stored at -80ºC.  RNA was 
extracted by chloroform and RNA precipitated from the aqueous phase using 
isopropyl acohol.  In some instances 5µg glycogen was added to the aqueous 
phase prior to precipitation. RNA was quantified spectrophotometrically using a 
Nanodrop. cDNA was generated using iScript™ from Bio-Rad, and expression 
was assessed by qRT-PCR using a SYBR Green system. Primers were 
purchased from Qiagen (human18s rRNA, murine 18s rRNA, murine Eomes, 
human and murine HDAC1-11) or custom made: HDAC11: Forward: 
ACACGAGGCGCTATCTCAAC, Reverse: ACGCGTTCAAACAGGAACTT; 
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Eomes forward: AGGCGCAAATAACAACAACACC, Reverse: 
TCAAGTCCTCCACGCCATC; Granzyme B forward: 
TGCTGCTAAAGCTGAAGAGTAAG, reverse: 
CGTGTTTGAGTATTTGCCCATTG; perforin: forward: 
GCTCCCACTCCAAGGTAGC, reverse: TTTGTACCAGGCGAAAACTGT 
 
Graft vs. Host Disease Model 
Total bone marrow cells were isolated from the tibia and femurs of 
C57BL/6 (H-2b) and total T-cells from spleens and lymph nodes by negative 
selection using the Easysep system. 6-8 week old BALB/c (H-2d) mice were 
lethally irradiated with 900cGy using a Cesium137 irradiator. One day later, 106 
bone marrow cells alone or BM plus indicated numbers of T-cells were 
administered by tail vein injection. Mice were weighed three times weekly and 
monitored for survival. For determination of T-cell expansion, spleens from 
recipient mice were harvested five days post adoptive transfer. To determine 
IFN-γ expressing cells, T-cells were stained for surface expression of CD4+ or 
CD8+, fixed and permeabilized, and stained for IFN-γ. Data was acquired using 
an LSRII  flow cytometer. To determine serum cytokine levels, mice were bled 
and analysis of indicated cytokines was performed by ELISA.  
 
Anergy Experiments 
 Splenic CD4+ T-cells were harvested from OTII or OTII/HDAC11KO 
transgenic mice, and 2.5x106 CD4+ T-cells were adoptively transferred to WT 
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C57BL/6 mice via tail vein injection. Two days following, mice were challenged 
with OVA peptide (Ile-Ser-Gln-Ala-Val-His-Ala-Ala-His-Ala-Glu-Ile-Asn-Glu-Ala-
Gly-Arg) or sham injection. Ten days following challenge, T-cells were harvested 
and co-cultured with WT spleenocytes in the presence of OVA peptide. Forty-
eight hours later, supernatants were collected and cytokine production assessed 
by a standard ELISA protocol.  
 
Antigen Specificity Experiments 
 Splenic CD4+ T-cells were harvested from OTII or OTII/HDAC11KO 
transgenic mice. T-cells were subsequently co-cultured with WT C57BL/6 
splenocytes in the presence of indicated concentrations of OVA. Twenty-four 
hours later supernatants were collected and IFN-γ production assessed by a 
standard ELISA protocol.  
 
eGFP Microscropy Analysis 
 Mouse lymph nodes were harvest and physically digested to obtain a 
single cell suspension. CD3+ T-cells were isolated by negative magnetic 
selection and plated with or without αCD3/CD28 beads in T-cell media or T-cell 
media supplemented with 20ng/mL IL-2. eGFP expression was assessed by an 
Incucyte kinetic imaging system from Essen Bioscience (Ann Arbor, MI). Data 
was analyzed using Incucyte software.  
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Determination of Lymphocyte Population Distribution 
 Mouse lymph nodes were extracted, and mashed through a 70µm cell 
strainer to achieve a single cell suspension. Cells were washed twice with PBS 
and resuspended in dPBS containing 2% FBS and 2mM EDTA (FACS buffer) 
containing flurochrome conjugated antibodies against the following cell surface 
markers: B220, CD3, CD45, CD4 and CD8. Cells were incubated at 4°C in the 
dark for 20 minutes. Cells were then washed with dPBS twice and resuspended 
in FACS buffer containing 74ng/mL DAPI. Data was acquired using an LSRII flow 
cytometer and analyzed using FlowJo software.  
 
Determination of Lymph Node Cellular Content 
 Mouse lymph nodes were extracted and mashed through a 70µm cell 
strainer to achieve a single cell suspension. Cells were centrifuged and 
resuspended in dPBS. A 10uL aliquot was taken and mixed with 10uL of trypan 
blue. Samples were pipetted onto a hemocytometer, placed on a brightfield 
micropscope and viable cells counted. Total cell counts were determine by 
multiplying the number of viable cells in one quadrant by a diluation factor of two, 
the constant value of 104, and the volume in milliliters of the original cell 
suspension. Counts from four independent experiments totaling nine mice per 
group were analyzed.  
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T-cell Proliferation Assays 
 T -cells were washed and resuspended in dPBS at a concentration of 
2x106 cells/mL. An equal volume of dPBS containing 2µM Cell Trace Violet 
(Invitrogen) or carboxyfluorescein diacetate succinimidyl ester (CFSE) was 
added to the cell suspension while vortexing. Cells were incubated at 37ºC and 
5% CO2 for 15 minutes then resuspended in fresh dPBS with 10% FBS. Cells 
were again incubated at 37ºC and 5% CO2 for additional 30 minutes, upon which 
T-cells were centrifuged and resuspended in T-cell media. Cells were cultured 
and stimulated with αCD3/CD28 Dynabeads (Invitrogen). After 72 hours, cells 
were stained with flurochrome-conjugated antibody against CD4 or CD8 and 
DAPI. Finally, proliferation data was acquired using a LSRII flow cytometer. 
Proliferation data was analyzed using FlowJo 7 software.  
 
Treg Inhibition Assay 
To determine susceptibility to Treg inhibition, CD4+CD25- T-cells from WT 
or HDAC11KO mice were purified by magnetic separation and CFSE-labeled. 
These cells where then activated by CD3/CD28 stimulation and co-cultured with 
indicated ratios of CD4+CD25+ Tregs isolated form WT or HDAC11KO mice. 
Proliferation of effector T-cells was analyzed by flow cytometry.  
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HDAC11 Overexpression 
Peripheral blood mononuclear cells from healthy donors were obtained by 
density gradient centrifugation over Ficoll-Paque™ Plus within 24 hours after 
blood collection. CD3+ T-cells were isolated by negative selection and used fresh 
or stored at -80oC. Over expression of histone deacetylase 11 (HDAC11) was 
performed by nucleofection of human T-cell using Amaxa® Human T Cell 
Nucleofector® Kit, as recommended by the supplier. A total of 107 unstimulated 
cells was transfected with 2.5ug of HDAC11-encoding plasmid or control empty 
vector using program U14. Media was replaced on the following morning and 
cells cells were stimulated with anti-CD3/CD28 Dynabeads. Activation was 
performed either 18 or 40 hours after transfection for cytokine production 
analysis or mRNA extraction, respectively. 
 
Cell Surface Marker Expression 
For surface marker analysis, T-cells were washed twice with PBS and 
resuspended in MACS (DPBS + 2mM EDTA + 2% FBS) buffer. Cells were 
stained with fluorchrome-conjugated antibodies against markers of interest. The 
following antibody conjugates were used: CD3 (PE-CY7), CD3 (PerCP), CD8 
(APC), CD44 (Alexafluor 700), CD62L (efluor 605), CD27 (FITC), CD127 (PE), 
KLRG1 (Alexafluor 488), B220 (PE), and CD45 (PE-CY7). After staining for 20 
minutes at 4ºC, cells were washed three times and then resuspended in buffer 
containing DAPI (50ng/mL) or 7-AAD (5µg/mL) for viability determination. A 
minimum of 10,000 events were collected using an LSR II (BD Biosciences, 
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Franklin Lakes, NJ) flow cytometer and subsequently analyzed using FlowJo 
software. 
 
Cytokine Production Profile 
For determination of T-cell cytokine production profile, a cytokine bead 
array was performed. CD4+ or CD8+ T-cells were isolated from WT or 
HDAC11KO mice by negative magnetic cell separation. Cells were plated for 72 
hours in the presence of αCD3/CD28 beads. Supernatants were collected and 
stored at -80ºC until time of use. Cytokine secretion was assessed by use of a 
murine Th1/Th2/Th17 flow cytometry based cytokine bead array (CBA) 
purchased from BD Biosciences. Manufacturer’s suggested protocol was 
adhered to. Data was collected using a FACSCalibur (BD Biosciences) flow 
cytometer. Standard curves were calculated and quantities values of cytokine 
production assessed by FCAP Array 3.0 software (BD Biosciences).  
 
Statistical Analysis 
Statistical analyses were conducted using GraphPad Prism v5.0 software. 
Unpaired t-tests were performed for experiments involving two groups. All 
experiments involving greater than two groups or more than one comparison 
were analyzed by one-way ANOVAs. Log rank analysis was performed for 
survival curves.  P-values of less than 0.05 were considered significant.  
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Results 
 
T-cells have a Distinct HDAC Expression Profile 
 Given the results shown earlier that inhibition of HDACs by LBH589 can 
lead to profound increases in IFN-γ production by T-cells as well as previous 
reports showing modulation of T-cell function with other HDAC inhibitors, the 
expression profile of HDACs in T-cells was initially determined to gain insight into 
potential regulators of T-cell function. As shown in figure 6A, murine T-cells have 
a distinct expression of individual HDACs. Similar results are also seen in human 
T-cells (figure 6B). Intriquingly, many HDACs appear to be down-regulated after 
activation, with the exception of HDAC7.  
 
 
 
Figure 6. T-cells have distinct expression of individual HDACs.  CD3+ T-cells 
isolated from mouse lymph nodes (A) or human healthy donor peripheral blood (B) 
were lysed and expression of individual HDACs was assessed by qRT-PCR.  
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T-cells have Differential Expression of HDAC11 According to Developmental 
Stage, Subset and Activation State 
Given the absence of knowledge of its role in T-cells, expression of 
HDAC11 was further investigated. Using an eGFP-reporter mouse system 
HDAC11 expression differences in T-cell subsets was initially characterized. To 
first ensure that the T-cell compartments of the transgenic eGFP-reporter mouse 
were normal, T-cell development and circulation with regards to distribution and 
number was investigated in the eGFP-reporter mouse strain. As seen in figure 
7A, eGFP-Reporter mice have normal thymic distributions of double negative, 
double positive and single positive T-cells. As well, as shown in figure 7B, eGFP 
reporter mice have normal numbers of circulating lymphocytes. These circulating 
lymphocytes have no significant difference in B-cell, CD4+, and CD8+ 
composition compared to wild-type mice (data not shown).  
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Figure 7. eGFP-HDAC11 reporter mice have normal T-cell compartments. (A) 
eGFP-reporter and WT mice thymic distribution of CD4+ and CD8+ expression 
was compared by flow cytometry.(B) Complete blood analysis of peripheral blood 
lymphocytes was done to compare circulating levels of lymphocytes.  
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Expression of eGFP-HDAC11 was next investigated in the primary and 
secondary lymphoid organs. To this end, the double negative thymocyte 
population, the earliest stage of thymocytes, had very few eGFP-HDAC11 
expressing cells (Figure 8A). The percentage of eGFP-HDAC11 expressing cells 
then increases steadily with developmental progression, with double positive 
thymocytes possessing an increased, but still relatively low population of eGFP-
HDAC11 expressing cells, and single positives thymocytes having an even 
higher percentage. Expression of eGFP-HDAC11 in mature CD4+ and CD8+ 
shows that this trend of increased eGFP-HDAC11 expression continues into the 
lymph nodes, with a nearly 50/50 distribution of expressing and non-expressing 
T-cells (Figure 8B). Similar results are seen for both CD4+ and CD8+ T-cells in 
peripheral blood and spleen (data not shown).  
To further the characterization of HDAC11 expression in T-cells, 
expression trends in CD4+ and CD8+ T-cell subsets was next addressed. 
Marked differences in eGFP-HDAC11 expression are seen according to memory 
status. Naïve (CD44-CD62L+) and central memory (CD44+CD62L+) T-cells of 
both CD4+ and CD8+ lineages have a realtively large percentage of eGFP-
HDAC11 expressing cells, maintaining the 50/50 disbribtuion seen in whole T-cell 
populations (Figure 8C). However, a reduction in eGFP-HDAC11 expressing 
population is seen in effector (CD44-CD62L-) and, even more so, in effector 
memory (CD44+CD62L-) subsets. While the results shown are from T-cell 
isolated from lymph nodes, similar results are seen in both peripheral blood and 
spleen T-cells (data not shown).  
	  	   76	  
To confirm that the results seen using eGFP-HDAC11 reporter cells are 
truly indicative of HDAC11 expression, HDAC11 mRNA expression was 
assessed in the eGFP- and eGFP+ populations from double positive thymocytes 
and single positive lymphocytes. As seen in figure 9D, eGFP+ cells have 
profoundly higher levels of HDAC expression relative to eGFP- cells.  
As the expression of HDAC11 is reduced in T-cell subsets with an effector 
phenotype, it was hypothesized that activation of T-cells may result in a similar 
decrease in HDAC11 expression. To test this hypothesis, total CD3+ T-cells from 
eGFP-HDAC11 reporter mice lymph nodes were activated by CD3/CD28 
stimulation. As seen in figure 9A, activation resulted in a marked decreased in 
eGFP-HDAC11 expression. To ensure that T-cell death in the absence of 
stimulation was not confounding results, samples plated in the presence of IL-2 
were also analyzed. Results were similar to those seen in the absence of IL-2.  
To again confirm that eGFP expression is indicative of HDAC11 expression, total 
CD3+ T-cells from WT mice were isolated, activated in the same fashion, and 
HDAC11 expression assessed by qRT-PCR. As seen in figure 9B, HDAC11 
expression is rapidly decreased post-activation. Human T-cells demonstrated 
similar decreases in HDAC11 expression post-activation (Figure 9C). 
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Figure 8. T-cells have differential expression of HDAC11 based on 
developmental stage and subtype.  Using an eGFP-HDAC11 reporter mouse 
strain, percentages of eGFP+ thymocytes (A), lymphocytes harvest from lymph 
nodes (B,C) were determined by flow cytometry. Thymus and lymph node 
populations were flow sorted based on eGFP expression and HDAC11 mRNA 
qualified by qRT-PCR (D).  
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Figure 9. Activation of T-cells results in decreased HDAC11 expression.  Using 
an eGFP-HDAC11 reporter mouse strain, CD3+ T-cells were plated with or without 
CD3/CD28 beads and 20ng/mL IL-2 for 17 hours and imaged by florescence 
microscopy (A). CD3+ T-cells were isolated from three wild-type mice (B) or three 
health human buffy coats (C) and stimulated with CD3/CD28 beads for indicated 
times. HDAC11 mRNA expression was assessed by qRT-PCR. ***p<0.001.  
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HDAC11 Expression is Independent of Ki67 Expression  
 Previous reports have shown a negative correlation in HDAC11 and Ki67 
expression in the brain of mice146. This suggests that HDAC11 may play a role in 
cell proliferation. To address this hypothesis eGFP-HDAC11 expressing and non-
expressing populations of T-cells were sorted and analyzed for Ki67 expression 
(Figure 10).  Unsurprisingly, in non-stimulated T-cells, both eGFP-HDAC11 
positive (shown in red) and negative populations (shown in blue) have minute 
expression of Ki67. In CD3/CD28 stimulated T-cells, both populations have Ki67 
expressing subpopulations. However, a slightly increased percentage of eGFP-
HDAC11 negative cells are Ki67+.  
 
 
 
Figure 10. eGFP-HDAC11 expression is not correlated with Ki67 expression. 
Using an eGFP-HDAC11 reporter mouse strain, T-cells were sorted into eGFP 
expressing (red histograms) and non-expressing populations (blue histograms) by 
flow cytometry cell sorting. Cells were left unstimulated or stimulated with 
αCD3/CD28 beads for 36 hours. Cells were then fixed, stained, and analyzed for Ki67 
expression by flow cytometry. Non-stimulated CD8+ and stimulated CD3+ results 
shown are representative of multiple samples.  
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HDAC11 Knockout Mice have No Gross Phenotypic Abnormalities 
To elicit the function of HDAC11 in T-cells, an HDAC11 knockout 
(HDAC11KO) mouse strain was utilized. Merck Research Laboratories generated 
this HDAC11KO strain though the use of a cre-recombinase system. In this 
mouse strain, cre-recombinase is driven by the constitutively expressed Rosa26 
promoter. Loxp recognition sites flank the third exon of the HDAC11 gene, 
resulting in a floxed region of the gene (Figure 11A).  This ultimately results in a 
whole-mouse, targeted deletion of the third exon of the HDAC11 gene and the 
introduction of a pre-mature stop codon. Confirmation of HDAC11KO is done by 
PCR using a two primer system. The anti-sense primer of the first primer set 
binds to a region inside the third exon, resulting the absence of a band in 
HDAC11KO mice. The second of the primer sets amplifies regions on either side 
of the third exon resulting in a truncated, but present band in the HDAC11KO 
mice (Figure 11B). Figure 11C shows qRT-PCR confirmation of HDAC11KO in T-
cells. Phenotypically, HDAC11KO mice are viable and healthy and present no 
overt impairments or disease states, with the exception that these mice tend 
towards development of intestinal inflammation at advanced ages (data not 
shown).  
Given the aforementioned results demonstrating a dynamic role of 
HDAC11 in T-cell development and activation, the gross distribution of T-cells in 
primary and secondary lymphoid organs was investigated. Surprisingly, 
HDAC11KO mice show no defects in thymic, spleen or lymph node distribution of 
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CD4+ and CD8+ cells (Figure 11D). As well, no differences in circulating 
lymphocyte numbers or T-cell and B-cell populations comprising them were seen 
(Figure 11E,F,G). However, it was noted upon dissection that lymph nodes from 
HDAC11KO mice often appeared enlarged relative to age matched WT mice. 
Indeed, as seen in Figure 11H, total cellular content from lymph nodes of 
HDAC11KO mice is elevated compared to that of WT mice.  
 
HDAC11KO Mice have Increased Percentages of Memory T-cells 
While no differences in overall distributions of CD4+ and CD8+ T-cells 
were noted in the HDAC11KO mouse strain, given the increased lymph node 
cellularity seen in HDAC11KO mice, the makeup of these populations was further 
compared. To accomplish this, populations of CD44 and CD62L expressing cells 
in CD4+ and CD8+ T-cells were assessed in both young and advanced age mice. 
As shown in Figure 12A, no differences are seen in young CD4+ mice, while 
HDAC11KO mice with advanced age have an increased population of 
CD44+CD62L- (effector memory) cells. In the CD8+ compartments, however, 
increased percentages of CD44+CD62L+ (central memory) T-cells are seen in 
both the young and aged HDAC11KO mice.  
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Figure 11. HDAC11KO mice have normal T-cell compartments with the 
exception of increased lymph node cellularity.  HDAC11KO mice were generated 
by use of a cre-recombinase system. The third exon of the HDAC11 gene is floxed 
and resultantly targeted for deletion (A). Confirmation of KO status is done by PCR 
using a two primer set system in which the first set recognizes regions of the third 
exon and is therefor absent in HDAC11KO mice (B). Further confirmation of KO 
status in T-cells isolated from HDAC11KO mice was done by qRT-PCR (C). Using 
flow cytometry, distribution of CD4+ and CD8+ cells was assessed in indicated 
lymphoid organs (D). Additionally, numbers of circulating lymphocytes was 
determined by CBC (E) and cell types comprising these numbers further evaluated by 
surface staining with indicated markers and assessment by flow cytometry (F,G). 
Lymph node cellular content was assessed in mice by hemocytometer counting of 
digested lymph nodes (H). 
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Figure 12. HDAC11KO mice have increased levels of memory T-cells. Lymph 
nodes isolated from WT and HDAC11KO mice of indicated ages were stained for 
CD3, CD4, CD8, CD62L and CD44 expression. Memory, effector, and naïve 
populations of T-cells were assessed by flow cytometry. Results shown are indicative 
of those from multiple mice (A). Further staining of CD27, CD127 or KLRG1 in 
addition to those listed above was performed. Expression of indicated markers was 
assessed by flow cytometry (B).  
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To further characterize the naïve (CD44-CD62L+) and central memory 
(CD44+CD62L+) compartments of HDAC11KO mice, expression of several 
important receptors was evaluated (Figure 12B). CD27 (TNF receptor) levels 
appeared normal, in both compartments of CD8+ T-cells, and nearly so in CD4+ 
compartments, with the exception of a reduced number of CD27low cells in the 
central memory compartment of HDAC11KO T-cells. As well, CD127 (IL-7 
receptor) expression appears normal in all compartments. KLRG1, an inhibitory 
molecule also described as a terminal differentiation marker273, expression 
appeared normal in CD4+ and naïve CD8+ T-cells. In CD8+ central memory T-
cells, a mildly increased level of KLRG1high cells is seen.  
 
HDAC11KO T-cells have Enhanced Type 1 Effector Function 
In order to determine the role of HDAC11 in the effector function of T-cells, 
HDAC11KO mouse T-cells were activated via CD3/CD28 beads. As shown in 
Figure 13A, both CD4+ and CD8+ T-cells isolated from HDAC11KO had higher 
levels of proliferation than WT controls. In addition to a greater population of cells 
proliferating, those cells that did proliferate proliferated more on average in the 
HDAC11KO samples (CD8+ proliferative indexes: WT:1.74, HDAC11KO: 1.97).  
Also assessed was loss of CD62L post activation, a phenotypic change 
associated with migration from the lymph nodes and acquisition of lytic 
function274. As seen in figure 13B, at 24 hours of stimulation, both CD8+, and 
more so CD4+ T-cells from HDAC11KO mice have higher percentages of T-cells 
that have shed CD62L. Importantly, cytokine production by T-cells lacking 
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HDAC11 was also analyzed. As shown in figure 13C both CD4+ and CD8+ T-
cells from HDAC11KO mice produce significantly higher levels of IL-2, TNF, and 
most profoundly IFN-γ. Data shown is from 72 hours of stimulation. No 
differences in IL-6, IL-4, IL-10, or IL-17 were seen (data not shown). Additionally, 
T-cells from both WT and HDAC11KO mice with no stimulation for a 
corresponding amount of time produced no detectable levels of cytokine (data 
not shown). Finally, expression of the effector molecules granzyme B and 
perforin was assessed in CD8+ T-cells. HDAC11KO CD8+ T-cells produced 
higher levels of message for both molecules (Figure 13D). Intriguingly, 
expression of both genes was elevated even at the basal state. To address the 
antigen specificity and threshold of activation, antigen specific OTII or 
OTII/HDAC11KO CD4+ T-cells were co-cultured with APCs presenting cognate 
OVA antigen. As shown in Figure 13E, no production of IFN-γ was seen in either 
OTII or OTII/HDAC11KO T-cells without OVA antigen. In the presence of OVA 
antigen, HDAC11KO T-cells produced higher levels of IFN-γ, and did so at lower 
concentrations of antigen at the 24-hour time point. However, at 48 hours, the 
lowest dose of OVA peptide did result in detectable, albeit lower levels of IFN-γ 
(data not shown).  
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Figure 13. HDAC11KO T-cells have increased type 1 effector functions. CD4+ or 
CD8+ T-cells were isolated from 10 week old WT or HDAC11KO mice and activated 
with CD3/CD28 beads. Cells stained with proliferation tracking dye were assessed by 
flow cytometry for division after 72 hours of stimulation (A). T-cells were assessed for 
CD62L expression by flow cytometry both at the basal state and after 24 hours of 
stimulation (B). Supernatants were harvested after 72 hours of stimulation and 
cytokine production assessed by cyometric bead assay (C). Granzyme B and perforin 
mRNA from T-cells stimulated for 6 hours or without stimulation was assessed by 
qRT-PCR (D). Ova-antigen-specific CD4+ T-cells from OTII or OTII/HDAC11 mice 
were cultured with wild-type APCs pulsed with indicated concentrations of OVA 
peptide. Twenty-four house later IFN-γ production was assessed by ELISA. *p<0.05, 
**p<0.01, ***p<0.001. 
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HDAC11KO T-cells are Resistant to Anergy and Treg Suppression  
As stated to previously, even with recognition of tumor antigen by T-cells, 
several factors of the suppressive tumor microenvironment must be overcome for 
the immune response to be effective. To this end, the ability of T-cells lacking 
HDAC11 to overcome two of these mechanisms, inhibition by Tregs and anergy 
formation, were tested. As shown in Figure 14A, mixed lymphocyte reactions with 
HDAC11KO Teff cells cocultured with WT Tregs result in a lesser degree of 
proliferation inhibition than when WT Teff cells are cocultured with WT Tregs. 
However, in Figure 14B, mixed lymphocyte reactions of WT Teff cells with either 
WT Tregs or HDAC11KO Tregs showed no differences in proliferation inhibition, 
supporting the conclusion that HDAC11KO natural Tregs are not distinct from 
WT natural Tregs in their ability to suppress Teff cells.  
 Experiments next addressed the ability of HDAC11KO T-cells to resist 
anergy formation. Using antigen specific CD4+ WT or HDAC11KO T-cells and 
high dose OVA peptide in vivo, cells were tested for their recall ability when re-
challenged ex vivo. Figure 14C shows that when T-cells with HDAC11 (OTII) 
were re-challenged (+Ova groups) there was a reduction in IL-2 production 
compared to non-initially-challenged (-Ova) and no IFN-γ production, 
demonstrating anergy induction. However, T-cells lacking HDAC11 
(OTII/HDAC11KO) had increased levels of IL-2 and IFN-γ in the re-challenged 
group compared to non-initially challenged, demonstrating a robust resistance to 
anergy formation. Additionally, in agreement with previous experiments, 
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OTII/HDAC11KO T-cells produced higher levels of both cytokines in the non-
initially challenged groups compared to OTII T-cells.  
 
 
 
 
 
Figure 14. T-cells lacking HDAC11 have lessened susceptibility to Treg 
inhibition and anergy formation.  T-cells isolated from WT or HDAC11KO mice 
were labeled with the proliferation tracker CFSE and CD3/CD28 activated in the 
presence of indicated ratios with WT CD4+ Tregs. Reduction in percentages of 
proliferating cells relative to those at the 0:1 Treg:Teff ratio were graphed (A). In a 
similar manner WT Teff cells were co-cultured with increasing ratios of WT or 
HDAC11KO Tregs (B). CD4+ T-cells from OTII or OTII/HDAC11 transgenic mice 
were adoptively transferred into lympho-depleted C57BL/6 WT recipients. Two days 
following mice were challenged with high dose OVA peptide (+Ova) or sham injection 
(-Ova) in vivo. Ten days following challenged, CD4+ T-cells were harvested from 
mice and co-cultured with WT spleenocytes pulsed with OVA peptide. Forty-eight 
hours following this, cytokine production was assessed by ELISA.  
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HDAC11KO T-cells Induce a Robust and Potent Graft vs. Host Disease 
Given the in vitro data demonstrating the potency of HDAC11KO T-cells, it 
was next determined whether these results would carry over in an in vivo model. 
Initially, this was done using a graft vs. host disease model (GvHD). To this end, 
Balb/c mice received myloablative irradiation and subsequently received adoptive 
transfers of CD57BL/6 bone marrow (BM) with or without one million T-cells from 
WT or HDAC11KO donors. As seen in Figure 15A, mice receiving T-cell adoptive 
transfers succumbed to GvHD as shown by a reduced survival time 
characterized by reduced body mass. However, those mice receiving adoptive 
transfers of HDAC11KO T-cell populations succumbed more rapidly and had a 
greater rate of body mass decrease than those receiving WT T-cell populations. 
To further these results, a similar experiment was performed; however, reduced 
numbers of T-cells were given to recipient mice. As seen in Figure 15B, adoptive 
transfers of 0.5 and 0.25 million HDAC11KO T-cells were still able to induce 
GvHD resulting in decreased survival and body mass loss. At these titrations, 
these results were absent in the WT T-cell recipients.  
 To characterize the enhanced GvHD seen in HDAC11KO T-cell recipients, 
several parameters were addressed ex vivo. Five days post adoptive transfer, 
higher absolute numbers of T-cells are seen in the spleens of HDAC11KO 
recipient mice (Figure 15C). Additionally, more of these T-cells were positive for 
IFN-γ production in the HDAC11KO recipients (Figure 15D). Finally, assessment 
of IFN-γ and TNF levels demonstrate increased levels of both cytokines in the 
serum of HDAC11KO T-cell recipient mice (Figure 15E).  
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Figure 15. HDAC11KO T-cells mediate a more robust and potent GvHD. BALB/c 
mice were lethally irradiated and transplanted with 5×106 C57BL/6 mouse BM cells 
depleted of T-cells and 1×106 (A) or 0.5 and 0.25 × 106 (B) WT or HDAC11KO T 
cells. Mice survival and body weight were monitored. Splenic T-cell numbers at day 5 
after BM and 0.5× 106 T-cell transplantation were assessed (C). The number of IFN-γ 
positive T-cells at day 5 was assessed by intracellular flow cytometry of splenocytes 
stimulated with PMA/Ionomycin (D). Mice serum TNF-α and IFN- γ concentrations at 
day 12 after being transferred with BM and 0.5× 106 T cells were assessed (E).  
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HDAC11KO T-cells have Enhanced Anti-tumor Activity In Vivo 
Next, the anti-tumor efficacy of HDAC11KO T-cells was determined. To 
this end, the syngeneic, B16 murine melanoma tumor model was utilized. As 
seen in Figure 16A, B16 melanoma bearing mice who receive adoptive transfers 
of WT T-cells have delayed tumor progression compared to mice receiving no 
adoptive transfer, while mice receiving adoptive transfers of HDAC11KO T-cells 
have a even greater and significant reduction in tumor progression. As shown in 
Figure 16B, this results in a survival advantage for HDAC11KO recipients in 
comparison to WT recipients.  
 
 
 
 
 
Figure 16. HDAC11KO T-cells have increased anti-melanoma activity in vivo.  
C57BL/6 mice were injected with 100,000 B16 melanoma cells subcutaneously. After 
tumors become visible, mice were sub-lethally irradiated and 5x106 T-cells isolated 
from WT or HDAC11KO were adoptively transferred via tail vein injection the 
following day, or a sham injection given. These T-cells had been CD3/CD28 activated 
for 72 –hours prior to transfer. Tumor measurements were made three times weekly 
(A) and survival was monitored (B).  
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No differences in TCR signaling are Present in HDAC11KO T-cells 
In order to gain insight into the mechanistic difference(s) in HDAC11KO T-
cells that resulted in the phenotypes observed, basal and post-activation levels of 
T-cell receptor (TCR) and phosphorylated signaling proteins were investigated. 
No observable differences were noted in zeta chain components, linker of 
activation (LAT), SLP76 or ZAP70 expression at basal state and up to 15 
minutes post-activation (Figure 17A). Additionally, no differences in total CD3 or 
CD28 expression were noted when assessed by flow cytometry (data not shown). 
Furthermore, western blot analysis of signaling molecules again showed no 
differences between HDAC11KO and WT T-cells (Figure 17B).  
 
HDAC11KO T-cells have Enhanced Expression of the Transcription Factors T-
bet and Eomes 
Previous studies have demonstrated that the transcription factors T-bet 
and Eomes are important for type 1 effector function and memory development 
of T-cells. Consequently, the expression of these molecules was investigated. 
Expression of both Eomes (Figure 18A) and T-bet (Figure 18B) are significantly 
elevated in both CD4+ and CD8+ HDAC11KO T-cells. As expected, expression 
of both transcription factor significantly increases post stimulation. However, 
expression levels at the basal state are significantly higher in HDAC11KO T-cells.  
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Figure 17. HDAC11KO T-cells have normal expression of T-cell receptor 
proteins and signaling molecules. T-cells isolated from WT or HDAC11KO mice 
were CD3/CD28 stimulated for indicated time points, lysed and protein expression 
assessed by western blot. Blots were probed with 4G10 antibody against 
phosphotyrosine (A) against other indicated antigens (B). 
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Overexpression of HDAC11 in T-cells Results in Decreased T-bet Expression 
 Given that HDAC11KO T-cells express high levels of T-bet and Eomes, 
the influence of overexpression of HDAC11 in T-cells was assessed. To 
accomplish this, an HDAC11 plasmid was transfected into healthy human CD3+ 
T-cells. As seen in Figure 19A, transfection results in robust increases in 
HDAC11 expression compared to empty vector control transfection. 
Consequently, figure 19B and 19C show that overexpression also results in 
decreased expression of T-bet and Eomes, respectively, following activation of T-
cells.  
Figure 18. HDAC11KO T-cells have enhanced expression of Eomes and T-bet. 
CD8+ and CD4+ T-cells isolated from WT or HDAC11KO mice were left unstimulated 
or CD3/CD28 stimulated for six hours. mRNA expression of Eomes (A) and T-bet (B) 
was assessed by qRT-PCR.  
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Discussion 
This chapter has demonstrated a hereto-unknown role of HDAC11 in 
regulating both CD4+ and CD8+ T-cell effector response and memory 
development. The data presented shows that HDAC11 is highly expressed in 
resting, mature T-cells. Furthermore, HDAC11 expression is rapidly reduced 
following activation of T-cells, and remains low in resting effector and effector 
memory T-cells. These data also clearly show that T-cells lacking HDAC11 have 
a potent pro-inflammatory phenotype. While still reliant upon both recognition of 
MHC bound antigen and proper co-stimulation (data not shown), once activated 
HDAC11KO T-cells able to respond more rapidly and robustly. This robust 
response includes increased proliferation, increased secretion of type 1 cytokines, 
and increased production of perforin and granzyme B. Additionally, HDAC11KO 
T-cells are demonstrate higher degrees of resistance to Treg suppression of 
Figure 19. Overexpression of HDAC11 in T-cells results in decreased Tbet 
expression. Human CD3+ T-cells were transfected to overexpress HDAC11 
(HDAC11 O/E) or transfected with empty vector control (Empty). Transfected cells 
were activated with CD3/CD28 beads for six hours or left unstimulated. Cells were 
lysed and mRNA for HDAC11 (A), T-bet (B), and Eomes measured (C).  Results 
shown are representative of multiple samples.  
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proliferation and induction of anergy. Consequently, this enhanced pro-
inflammatory phenotype results in a robust and potent in vivo response in both 
GvHD and melanoma tumor models.   
Currently, the phenotype of HDAC11KO mice is unpublished. Here it is 
reported that HDAC11KO mice are grossly phenotypically normal, with the 
exception of a tendency to develop intestinal inflammation at advanced aged, 
which is hypothesized to be autoimmune in nature. Given the tendency of 
HDAC11KO T-cells to resist anergy and Treg suppression coupled with the hyper 
type-1 response of activated T-cells, it may initially seem counter-intuitive that 
these mice do not develop more robust and earlier autoimmunity. However, as 
previously reported, HDAC11 negatively regulates expression of IL-10 in APCs143. 
As such, the enhanced pro-inflammatory phenotype of HDAC11KO T-cells may 
be tempered by the anti-inflammatory phenotype of HDAC11KO APCs, though 
this hypothesis remains to be fully addressed experimentally. However, in 
support of this hypothesis, B16 melanoma growth in whole HDAC11KO mice is 
similar to that seen in WT mice (data not shown). This is in contrast to the effects 
of HDAC11KO T-cell adoptive transfer experiments reported here, in which 
HDAC11KO T-cells mediate a significant delay in tumor progression.  
Mechanistically, the results shown here demonstrate no differences exist 
in HDAC11KO TCR molecules or proteins involved in TCR signaling. 
Furthermore, no differences exist in expression of CD3, CD28, PD1, CTLA4, or 
OX40 (data not shown). Coupling these negative results with the data showing 
increased expression of T-bet and Eomes is increased in both CD4+ and CD8+ 
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HDAC11KO T-cells at the basal state and post-activation, it is proposed that his 
increased expression is driving the enhanced pro-inflammatory phenotype of 
HDAC11KO T-cells. Indeed, Eomes and T-bet are both known to positively 
regulate expression of IFN-γ275, and Eomes additionally is known to regulate 
granzyme B and perforin production in CD8+ T-cells276. Furthermore, both of 
these transcription factors are known to intimately involved in the formation of 
CD4+ and CD8+ memory subsets277-280.  This is inline with the data presented 
here that shows increased accumulation of memory subsets in HDAC11KO mice. 
In agreement with this hypothesis, HDAC11 overexpression results in a decrease 
in T-bet and Eomes expression in activated T-cells.  
With the proceeding results it is proposed that HDAC11 represents a 
figurative braking mechanism on T-cell effector response. To expand upon this 
hypothesized model: at the basal state, HDAC11 may function as part of a 
complex, similar in manner to previously described histone deacetylases, to 
maintain deacetylation of the histones at the Eomes and T-bet promoter regions, 
thereby restricting transcriptional activity. Upon activation of T-cells, this 
hypothesized complex dislocates, allowing for subsequent histone acetylation 
and ultimately expression of these genes. While the results of the experiment 
reported here support this model, work remains to be done to further support and 
elucidate the exact nature of the interaction of HDAC11 and the Eomes and T-
bet genes.  
Intriguingly, beyond it’s role in regulating effector response, the data 
presented suggests a role of HDAC11 in T-cell development, showing HDAC11 
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expression is low in early stages of thymic development and expression steadily 
increases with maturation. Indeed, currently unpublished data from our laboratory 
shows that HDAC11 expression is dynamic in various leukocyte and lymphocyte 
developmental lineages, with likely links to maturation and differentiation. 
However, the exact role(s) of HDAC11 in hematopoiesis and thymocyte 
development remains to be fully elucidated in future experiments. 
 Most importantly, these data strongly exemplify the need for development 
of iso-specific HDAC inhibitors, particularly against HDAC11. Development of 
such inhibitors would, on a broad scale, allow for easier and consequently more 
rapid investigation of the role of individual HDACs in both the basic biology of the 
immune system and in disease states and cells (e.g. cancer). More specifically, 
development of an HDAC11 inhibitor promises to allow for more effective 
immunotherapy, particularly in the setting of adoptive T-cell therapy.   
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CHAPTER 4 
Conclusions and Future Directions 
 
 The preceding contents of this dissertation have shown that targeting of 
histone deacetylases is an effective method of augmenting immunotherapy in 
melanoma. It is becoming increasingly clear that most targeted monotherapeutic 
approaches to cancer treatment are not effective at maintaining long-term 
remission. Inversely, many modern immunotherapeutic approaches to cancer 
treatment produce long-term remission, but only in a minority of patients. 
However, targeting histone deacetylases represents a dual approach to cancer 
therapy, preferentially targeting tumor cells for growth inhibition and cell death as 
well as enhancing the overall immune response. This enhanced immune 
response is not limited to the immunogenicity of tumor cells. Indeed, targeting of 
HDACs in APCs and T-cells enhanced both of these cell type’s pro-inflammatory 
function.  
While the selective growth inhibition and induction of cell death in 
transformed cells is a well reported phenomenon, the immunomodulatory effects 
of HDAC inhibition is a more recent and ongoing discovery. The contents here 
have shown that LBH589 is a highly potent and selective inhibitor of melanoma 
growth, but importantly also increases the immunogenicity of melanoma and 
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enhances the pro-inflammatory phenotype of immune cells. However, LBH589 
administration in murine models of melanoma was not able to cause tumor 
regression. It is to be sure that the reasons for this failing remain an important 
area for clarification if future application of LBH589, or HDAC mediated 
immunotherapy are to be truly successful. The failure may be the result of an 
overwhelmed immune system in which the progression of the tumor exceeds the 
killing capacity of the T-cells or the time needed to fully form an adaptive cellular 
immune response. If this case proves to be true, combination therapies with 
targeted agents such as Vemurafenib, may stall tumor progression for a duration 
that would allow full maturation of a T-cell arsenal, including memory, and 
resultantly long term tumor control and regression. Alternatively, the 
immunosuppressive functions of the melanoma cells may still remain too large of 
a hurdle to fully harness a pro-inflammatory response. If this proves to be the 
case, combination therapies with agents such as ipilimumab or PD1 blockade 
may prove to be effective.  
Previous reports using different HDAC inhibitors, and resultantly different 
levels of inhibition of differing HDACs, have reported opposite results. That is to 
say, the use of some HDAC inhibitors results in an anti-inflammatory immune 
phenotype. These contrasting results illustrate the complex and dynamic nature 
of HDACs. Through differential targeting of HDACs, opposite results can be 
achieved. This, arguably more than anything else, pleads the case for an 
increased understanding of the role of individual HDACs in different cells. In 
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response to this need, the role of the newest, and arguably least understood 
HDAC, HDAC11, was investigated.  
The results presented here have shown that HDAC11 is intimately tied to 
the function, specifically the pro-inflammatory function, of both CD4+ and CD8+ 
T-cells. Experimental evidence presented as well as circumstantial evidence 
suggests that this results from regulation of the transcription factors Eomes and 
T-bet. The results presented have also shown potential roles of HDAC11 in 
regulating thymocyte development and T-cell memory formation. Future 
investigations will need to further explore these potential roles. However, taken 
together, HDAC11 appears to be a rational target for inhibition in T-cells to 
improve immunotherapy. However, this relies heavily on future development of 
HDAC11 specific inhibitors, as such inhibitors are currently unavailable. Given 
the development of such inhibitors, it will be necessary to address key questions 
of their use in cancer immunotherapy. Indeed, given previous reports of HDAC11 
negatively regulating IL-10 production in macrophages, systemic administration 
may not be optimum. In such a case, ex vivo treatment of autologous T-cell 
adoptive therapy with a hypothetical HDAC11 inhibitor may prove to be a more 
effective administration. Alternatively, given reports of aberrant HDAC11 
expression in a variety of carcinomas and sarcomas141,150, systemic 
administration may result in a dual targeted approach as was seen with the pan-
HDACi LBH589. Regardless, these proposed experiments, and a further 
understanding of HDAC11’s biological roles, rely on the future development of a 
HDAC11 specific inhibitor. This in itself will likely rely on an increased 
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understanding of the nature of the HDAC11 protein. Unfortunately, while the 
HDAC11 gene is characterized, the protein product remains poorly characterized. 
This remains a major hurdle in development of selective HDAC11 inhibitors and 
consequently furthering of the scientific communities knowledge of HDAC11 
biology and the usefulness of therapeutic targeting.  
Overall, it is evident that HDACs are dynamic in their roles, with cell type, 
cellular localization, molecular partners, disease context, and various other 
intricacies affecting their ultimate function. It should be of no surprise that non-
specific targeting of HDACs can produce a spectrum of results dependent on 
these same factors. Thus, while currently available HDAC inhibitors should be 
continued to be systematically explored for their therapeutic potential, the field 
should be evolving towards more precise and deliberate targeting of HDACs to 
optimize therapeutic efficacy while avoiding unintentional side-effects. Such 
targeting holds the potential to allow directed manipulation of the immune 
response and, resultantly, therapies to a variety of diseases.  
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